

**UNITED STATES BANKRUPTCY COURT  
SOUTHERN DISTRICT OF NEW YORK**

**In re:**

**PURDUE PHARMA L.P., et al.,**

**Debtors.<sup>1</sup>**

**Chapter 11**

**Case No. 19-23649**

**(Jointly Administered)**

**NOTICE OF TWENTY-FOURTH MONTHLY STATEMENT OF  
SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP  
FOR COMPENSATION FOR SERVICES RENDERED AND REIMBURSEMENT  
OF EXPENSES INCURRED AS SPECIAL COUNSEL TO THE DEBTORS  
FOR THE PERIOD FROM SEPTEMBER 1, 2021 THROUGH SEPTEMBER 30, 2021**

Name of Applicant:	Skadden, Arps, Slate, Meagher & Flom LLP
Authorized to Provide Services to:	Purdue Pharma L.P., et al.
Date of Retention:	November 25, 2019, <i>nunc pro tunc</i> to September 15, 2019
Period for Which Compensation and Expense Reimbursement is Sought:	September 1, 2021 through September 30, 2021
Amount of Compensation Requested:	\$1,142,189.10
Less 20% Holdback:	\$228,437.82
Net of Holdback:	\$913,751.28
Amount of Expense Reimbursement Requested:	\$39,210.45
Total Compensation (Net of Holdback) and Expense Reimbursement Requested:	\$952,961.73

<sup>1</sup> The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P., Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF L.P. (0495), SVC Pharma L.P. (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

In accordance with the Order Establishing Procedures for Interim Compensation and Reimbursement of Expenses for Retained Professionals, dated November 21, 2019 [Docket No. 529] (the “**Interim Compensation Order**”),<sup>2</sup> Skadden, Arps, Slate, Meagher & Flom LLP (“**Skadden**”) hereby submits this Twenty-Fourth monthly statement (the “**Twenty-Fourth Monthly Statement**”), seeking compensation for services rendered and reimbursement of expenses incurred as special counsel to the Debtors, for the period from September 1, 2021 through September 30, 2021 (the “**Twenty-Fourth Monthly Period**”). By this Twenty-Fourth Monthly Statement, and after taking into account certain voluntary discounts and reductions,<sup>3</sup> Skadden seeks payment in the amount of \$952,961.73 which comprises (i) 80% of the total amount of compensation sought for actual and necessary services rendered during the Twenty-Fourth Monthly Period and (ii) reimbursement of 100% of actual and necessary expenses incurred in connection with such services.

#### **SERVICES RENDERED AND EXPENSES INCURRED**

1. Attached hereto as **Exhibit A** is a summary of Skadden professionals by individual, setting forth the (a) name and title of each individual who provided services for the Twenty-Fourth Monthly Period, (b) aggregate hours spent by each individual, (c) hourly billing rate for each such individual at Skadden’s then-current billing rates, (d) amount of fees earned by each Skadden professional, and (e) year of bar admission for each attorney. The blended hourly

---

<sup>2</sup> Capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Interim Compensation Order.

<sup>3</sup> In addition to the volume discount, the total amount sought for fees and expenses (\$1,181,399.55) reflects voluntary reductions for this period of \$504.00 in fees and \$687.27 in expenses, for an overall voluntary reduction of 0.09%. Skadden reserves the right to request these amounts.

(cont’d)

billing rate of Skadden timekeepers during the Twenty-Fourth Monthly Period is approximately \$1,135.25<sup>4</sup>

2. Attached hereto as **Exhibit B** is a summary of the services rendered and compensation sought, by project category, for the Twenty-Fourth Monthly Period.
3. Attached hereto as **Exhibit C** is a summary of expenses incurred and reimbursement sought, by expense type, for the Twenty-Fourth Monthly Period.
4. Attached hereto as **Exhibit D** is itemized time records of Skadden professionals for the Twenty-Fourth Monthly Period and summary materials related thereto.

#### **NOTICE AND OBJECTION PROCEDURES**

5. Notice of this Twenty-Fourth Monthly Statement shall be given by hand or overnight delivery upon the following parties (the “**Application Recipients**”): (i) Purdue Pharma L.P., 201 Tresser Blvd, Stamford, CT 06901, Attn.: Jon Lowne, Email: [Jon.Lowne@pharma.com](mailto:Jon.Lowne@pharma.com); (ii) counsel to the Debtors, Davis Polk & Wardwell LLP, 450 Lexington Avenue, New York, New York 10017, Attn.: Christopher Robertson and Dylan Consla, Email: [christopher.robertson@davispolk.com](mailto:christopher.robertson@davispolk.com), [dylan.consla@davispolk.com](mailto:dylan.consla@davispolk.com); (iii) counsel to the Committee: (a) Akin Gump Strauss Hauer & Feld LLP, One Bryant Park, Bank of America Tower, New York, New York 10036-6745, Attn.: Arik Preis and Sara L. Brauner, Email: [apreis@akingump.com](mailto:apreis@akingump.com) and [sbrauner@akingump.com](mailto:sbrauner@akingump.com); and (b) Bayard, P.A., 600 N. King Street, Suite 400, Wilmington, DE 19801, Attn.: Justin R. Alberto and Daniel N. Brogan, Email: [jalberto@bayardlaw.com](mailto:jalberto@bayardlaw.com) and [dbrogan@bayardlaw.com](mailto:dbrogan@bayardlaw.com); and (iv) the Office of the United States Trustee, U.S. Federal Office Building, 201 Varick Street, Suite 1006, New York, New York

---

<sup>4</sup> The blended rate is comprised of all Skadden timekeepers who provided services during the Twenty-Fourth Monthly Period.

10014, Attn.: Paul K. Schwartzberg, Email: Paul.Schwartzberg@usdoj.gov. (collectively, the “**Notice Parties**”).

6. Objections to this Twenty-Fourth Monthly Statement, if any, must be served upon the Notice Parties, and by email, hand, or overnight delivery upon Skadden, Arps, Slate, Meagher & Flom LLP, 1440 New York Avenue NW, Washington, D.C. 20005, Attn.: Jennifer Bragg, Email: Jennifer.Bragg@skadden.com, 155 North Wacker Drive, Chicago, Illinois 60606, Attn.: Patrick Fitzgerald, Email: Patrick.Fitzgerald@skadden.com, One Rodney Square, 920 N. King Street, Wilmington, Delaware 19801, Attn.: Anthony W. Clark, Email: Anthony.Clark@skadden.com, and 525 University Avenue, Palo Alto, California, 94301, Attn.: Jennifer Madden, Email: Jennifer.Madden@skadden.com no later than November 22, 2021 at 12:00 p.m. (Prevailing Eastern Time) (the “**Objection Deadline**”), setting forth the nature of the objection and the specific amount of fees or expenses at issue.

7. If no objections to this Twenty-Fourth Monthly Statement are received by the Objection Deadline, the Debtors shall promptly pay Skadden 80% of the fees and 100% of the expenses identified in this Twenty-Fourth Monthly Statement.

8. To the extent that an objection to this Twenty-Fourth Monthly Statement is received on or before the Objection Deadline, the Debtors shall withhold payment of that portion of this Twenty-Fourth Monthly Statement to which the objection is directed and promptly pay the remainder of the fees and expenses in the percentages set forth above. To the extent such objection is not resolved, it shall be preserved and scheduled for consideration at the next interim fee application hearing.

Dated: November 8, 2021

SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP

/s/ Julie E. Cohen

Julie E. Cohen  
One Manhattan West  
New York, New York 10001  
Telephone: (212) 735-3000  
Fax: (212) 735-2000

– and –

Patrick Fitzgerald  
155 North Wacker Drive  
Chicago, Illinois 60606-1720  
Telephone: (312) 407-0700  
Fax: (312) 407-0411

– and –

Jennifer L. Bragg  
1440 New York Avenue, N.W.  
Washington, D.C. 20005  
Telephone: (202) 371-7000  
Fax: (202) 393-5760

*Special Counsel to Debtors  
and Debtors-in-Possession*

**EXHIBIT A**

**SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP**  
**PROFESSIONAL PERSON SUMMARY**  
SEPTEMBER 1, 2021 – SEPTEMBER 30, 2021

<u>NAME</u>	<u>YEAR OF ADMISSION</u>	<u>RATE</u>	<u>HOURS</u>	<u>AMOUNT</u>
<b>PARTNER</b>				
Jennifer L. Bragg	1996	1,565.00	155.00	\$ 242,575.00
Anthony W. Clark	1979	1,565.00	5.30	8,294.50
Patrick Fitzgerald	1986	1,775.00	73.00	129,575.00
Maya P. Florence	2004	1,425.00	96.90	138,082.50
Marie L. Gibson	1997	1,565.00	1.50	2,347.50
William (Bill) McConagha	1993	1,275.00	53.60	68,340.00
William Ridgway	2006	1,425.00	70.50	100,462.50
		<b>TOTAL PARTNER</b>	<b>455.80</b>	<b>\$ 689,677.00</b>
<b>OF COUNSEL</b>				
Karen C. Corallo	1984	1,175.00	2.50	\$ 2,937.50
		<b>TOTAL OF COUNSEL</b>	<b>2.50</b>	<b>\$ 2,937.50</b>
<b>COUNSEL</b>				
Michael S. Bailey	2007	1,260.00	1.20	\$ 1,512.00
John Boyle	1996	1,260.00	1.20	1,512.00
Avia M. Dunn	2008	1,260.00	41.50	52,290.00
		<b>TOTAL COUNSEL</b>	<b>43.90</b>	<b>\$ 55,314.00</b>
<b>ASSOCIATE</b>				
Pamela I. Amaechi	2019	695.00	3.30	\$ 2,293.50
William A. Bejan	2018	825.00	38.10	31,432.50
Elizabeth L. Berry	2016	995.00	95.70	95,221.50
Amanda H. Chan	2019	825.00	125.20	103,290.00
Barri Dean	2019	825.00	9.20	7,590.00
Lucy Dicks-Mireaux	2020	575.00	5.50	3,162.50
Emily Hellman	2017	995.00	100.90	100,395.50
Corbin D. Houston	2017	940.00	72.10	67,774.00
Kendall R. Ickes	2020	695.00	2.80	1,946.00
Jennifer Madden	2010	1,120.00	11.40	12,768.00
William S. O'Hare	2013	1,120.00	0.90	1,008.00
Lauren Oppenheimer	2018	825.00	0.70	577.50
Sterling M. Paulson	2018	825.00	72.20	59,565.00

Catherine Yuh	2020	695.00	1.50	1,042.50
<b>TOTAL ASSOCIATE</b>		<b>539.50</b>		<b>\$ 488,066.50</b>
<b><u>CLIENT SPECIALIST</u></b>				
William C. Terry	N/A	520.00	18.20	\$ 9,464.00
<b>TOTAL CLIENT SPECIALIST</b>			<b>18.20</b>	<b>\$ 9,464.00</b>
<b><u>PARAPROFESSIONALS</u></b>				
Denise Azadeh	N/A	250.00	6.00	\$ 1,500.00
Mark D. Campana	N/A	450.00	1.50	675.00
Matthew de Boer	N/A	250.00	6.30	1,575.00
William R. Fieberg	N/A	450.00	14.60	6,570.00
Michael J. Hohmann	N/A	450.00	13.10	5,895.00
Rachel Redman	N/A	450.00	16.50	7,425.00
<b>TOTAL PARAPROFESSIONALS</b>			<b>58.00</b>	<b>\$ 23,640.00</b>
<b>TOTAL</b>			<b>1,117.90</b>	<b>\$ 1,269,099.00</b>
<b>VOLUME DISCOUNT</b>				<b>\$ 126,909.90</b>
<b>TOTAL FEES</b>				<b>\$ 1,142,189.10</b>
<b>BLENDED HOURLY RATE \$1,135.25</b>				

**EXHIBIT B**

**COMPENSATION BY PROJECT CATEGORY  
(SEPTEMBER 1, 2021 – SEPTEMBER 30, 2021)**

<b>Project Category</b>	<b>Total Hours</b>	<b>Total Fees</b>
Bankruptcy Emergence Process	76.60	\$ 99,742.50
Bankruptcy Related Litigation and Regulation	701.10	766,936.00
Corporate/Transactional Matter	74.90	78,526.50
DOJ	108.50	160,857.00
General Advice	7.70	11,378.50
General Compliance	28.00	36,178.50
Healthcare Law Compliance	39.60	37,868.00
Litigation Discovery Issues	2.00	2,550.00
Project Catalyst	4.60	4,502.00
Retention/Fee Matter	56.40	60,483.00
Rhodes Companies	0.80	1,140.00
Various Texas Actions	17.70	8,937.00
<b>TOTAL</b>	<b>1,117.90</b>	<b>\$1,269,099.00</b>
<b>VOLUME DISCOUNT</b>		<b>\$ 126,909.90</b>
<b>TOTAL FEES</b>		<b>\$1,142,189.10</b>

**EXHIBIT C**

**SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP**  
**EXPENSE SUMMARY**  
**(SEPTEMBER 1, 2021 – SEPTEMBER 30, 2021)**

<b>Expense Category</b>	<b>Total Expenses</b>
Reproduction-color (@\$0.10 per page)	\$ 16.70
Outside Reproduction	6,726.31
Electronic Document Management	2,467.44
Secondment of Skadden Attorney	30,000.00
<b>TOTAL</b>	<b>\$ 39,210.45</b>

**EXHIBIT D**

**TIME DETAIL**

Purdue Pharma L.P.  
Bankruptcy Emergence Process

**Bill Date:** 11/03/21  
**Bill Number:** 1871283

NAME	DATE	HOURS	DESCRIPTION
BRAGG JL	09/01/21	1.10	CONFER WITH CO COUNSEL REGARDING CHANGE OF CONTROL ISSUES (1.1).
BRAGG JL	09/02/21	1.20	CONFER WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (1.2).
BRAGG JL	09/07/21	1.60	CONFER WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (0.9); ATTENTION TO CHANGE OF CONTROL REGULATORY ISSUES (0.7).
BRAGG JL	09/09/21	1.40	CONFER WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (0.6); REVIEW AND ANALYSIS OF CHANGE OF CONTROL ISSUES (0.8).
BRAGG JL	09/13/21	2.10	CONFER WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (0.4) CONFER WITH CLIENT RE: CHANCE OF CONTROL ISSUES(0.7); CALL WITH CLIENT RE: REGULATORY ISSUES ASSOCIATED WITH CHANGE OF CONTROL (1.0).
BRAGG JL	09/15/21	0.80	CONFER WITH CO-COUNSEL RE: LICENSING ISSUES (0.8).
BRAGG JL	09/16/21	0.60	CONFER WITH CO- COUNSEL RE: LICENSING ISSUES (0.6).
BRAGG JL	09/23/21	1.00	CONFER WITH CLIENT RE: LICENSING ISSUES (1.0).
BRAGG JL	09/24/21	1.80	CONFER WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (1.2); CALL WITH CLIENT RE: CHANGE OF CONTROL ISSUES (0.6).
BRAGG JL	09/27/21	1.60	CONFER WITH CLIENT RE: CHANGE OF CONTROL ISSUES (1.0); CONFER WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (0.6).
		<b>13.20</b>	
FLORENCE MP	09/01/21	0.30	CORRESPOND WITH CO-COUNSEL RE: LICENSING (0.3).

## Skadden, Arps, Slate, Meagher &amp; Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FLORENCE MP	09/02/21	1.10	CALL WITH A. DUNN AND CONSULTANT RE: LICENSING (0.3); CALL WITH A. DUNN RE: SAME (0.2); CORRESPOND WITH CLIENT AND CO-COUNSEL RE: SAME (0.3); REVIEW AND EDIT MATERIALS RE: SAME (0.3).
FLORENCE MP	09/03/21	0.40	CORRESPOND WITH CLIENT AND CO-COUNSEL RE: CHANGE OF CONTROL PROCESS (0.4).
FLORENCE MP	09/07/21	0.50	CORRESPOND WITH CLIENT AND CO-COUNSEL RE: CHANGE OF CONTROL PROCESS (0.5).
FLORENCE MP	09/08/21	0.90	CORRESPOND WITH CLIENT RE: CHANGE OF CONTROL PROCESS (0.5); PARTICIPATE IN CALL WITH CLIENT AND CONSULTANT RE: LICENSING (0.4).
FLORENCE MP	09/09/21	1.10	CALL WITH CONSULTANT RE: LICENSING (0.4); CALL WITH SKADDEN TEAM RE: LICENSING (0.4); CONFER WITH CLIENT RE: CHANGE OF CONTROL PROCESS (0.1); CORRESPOND WITH CLIENT RE: SAME (0.2).
FLORENCE MP	09/10/21	0.20	REVIEW AND COMMENT ON DRAFT LICENSING MATERIAL (0.2).
FLORENCE MP	09/13/21	2.10	PREPARE FOR CALL WITH CLIENT RE: LICENSING (0.2); PARTICIPATE IN CALL WITH CLIENT RE: SAME (0.3); PARTICIPATE IN CALL WITH CLIENT AND CO-COUNSEL RE: CHANGE OF CONTROL PROCESS (0.8); PARTICIPATE IN CALL WITH CLIENT RE: CHANGE OF CONTROL PROCESS (0.8).
FLORENCE MP	09/15/21	0.70	CONFER WITH A. DUNN AND J. BRAGG RE: LICENSING (0.6); CORRESPOND WITH CO-COUNSEL RE: CHANGE OF CONTROL PROCESS MATERIAL (0.1).
FLORENCE MP	09/16/21	0.30	CORRESPOND WITH CLIENT AND CO-COUNSEL RE: CHANGE OF CONTROL PROCESS (0.1); REVIEW AND EDIT DRAFT MATERIAL RE: SAME (0.2).
FLORENCE MP	09/17/21	1.20	REVIEW AND COMMENT ON DRAFT MATERIAL RE: CHANGE OF CONTROL PROCESS (0.2); PARTICIPATE IN CALL WITH CLIENT AND CO-COUNSEL RE: CHANGE OF CONTROL ISSUE (1.0).
FLORENCE MP	09/19/21	0.40	CORRESPOND WITH CO-COUNSEL RE: LICENSING (0.4).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**

ATTORNEY WORK PRODUCT

**PRIVILEGED AND CONFIDENTIAL**

FLORENCE MP	09/20/21	0.90	PARTICIPATE IN WEEKLY CALL RE: CHANGE OF CONTROL ISSUE (0.6); CONFER WITH CLIENT RE: SAME (0.2); CORRESPOND WITH CLIENT AND CO-COUNSEL RE: LICENSING (0.1).
FLORENCE MP	09/21/21	0.30	CORRESPOND WITH CLIENT RE: LICENSING (0.1); CORRESPOND WITH CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (0.2).
FLORENCE MP	09/22/21	0.70	PARTICIPATE IN WEEKLY CALL WITH CLIENT AND CONSULTANT RE: LICENSING (0.7).
FLORENCE MP	09/23/21	0.80	CORRESPOND WITH CLIENT AND CO-COUNSEL RE: CHANGE OF CONTROL ISSUES (0.5); REVIEW AND EDIT MATERIAL RE: LICENSING(0.3).
FLORENCE MP	09/24/21	2.10	CORRESPOND WITH CLIENT RE: CHANGE OF CONTROL ISSUE (0.3); PARTICIPATE IN CALL WITH CLIENT AND SKADDEN TEAM RE: SAME (1.3); CORRESPOND WITH SKADDEN TEAM RE: SAME (0.2); CONFER WITH CO-COUNSEL RE: SAME (0.3).
FLORENCE MP	09/27/21	1.80	PARTICIPATE IN WEEKLY GOVERNMENT CONTRACTS CALL (0.3); CONFER WITH A. DUNN RE: CHANGE OF CONTROL ISSUE (0.1); CORRESPOND WITH CLIENT AND A. DUNN RE: LICENSING (0.4); PARTICIPATE IN CALL WITH CLIENT RE: CHANGE OF CONTROL PROCESS (1.0).
FLORENCE MP	09/28/21	0.30	REVIEW AND COMMENT ON DRAFT LETTER RE: LICENSING (0.3).
FLORENCE MP	09/29/21	0.40	CORRESPOND WITH SKADDEN TEAM AND CLIENT RE: CHANGE OF CONTROL PROCESS (0.4).
		<b>16.50</b>	
MCCONAGHA W	09/02/21	0.80	EMAILS ON TRANSITION ISSUES (0.8).
MCCONAGHA W	09/07/21	2.30	RESEARCH AND ANALYZE TRANSACTIONAL ISSUE (2.3).
MCCONAGHA W	09/07/21	0.50	EMAILS ON TRANSITION ISSUES (0.5).
MCCONAGHA W	09/08/21	0.40	CORRESPOND RE: REGULATORY ENGAGEMENT (0.4).
MCCONAGHA W	09/08/21	0.50	REVIEW MATERIAL RE: TRANSITION (0.5).
MCCONAGHA W	09/08/21	0.50	REVIEW MATERIALS RELATED TO REGULATORY ENGAGEMENT (0.5).

## Skadden, Arps, Slate, Meagher &amp; Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

MCCONAGHA W	09/13/21	1.00	CALL WITH CO-COUNSEL ON PENDING REGULATORY TRANSITION ISSUE (1.0).
MCCONAGHA W	09/14/21	0.50	EMAILS WITH CO-COUNSEL ON TRANSITION ISSUES (0.5).
MCCONAGHA W	09/15/21	0.50	PREPARE FOR CALL RE: TRANSITION ISSUES (0.2); CALL FDA ON TRANSITION ISSUES (0.3).
MCCONAGHA W	09/16/21	0.80	CORRESPOND RE: TRANSITION ISSUES (0.8).
MCCONAGHA W	09/21/21	0.50	MEETING WITH CO-COUNSEL ON DEA REGULATORY ISSUES (0.5).
MCCONAGHA W	09/24/21	2.80	CALLS WITH CO-COUNSEL AND RELATED RESEARCH ON TRANSITION ISSUES (2.8).
MCCONAGHA W	09/27/21	1.00	CALL WITH CO-COUNSEL ON REGULATORY TRANSITION ISSUES (1.0).
MCCONAGHA W	09/27/21	0.50	RESEARCH ON FDA TRANSITION ISSUE (0.5).
MCCONAGHA W	09/27/21	2.50	DRAFT AND REVISE TALKING POINTS FOR DEA CALL (2.5).
MCCONAGHA W	09/29/21	0.80	CORRESPOND RE: TRANSITION ISSUES (0.8).
		<b>15.90</b>	
<b>Total Partner</b>		<b>45.60</b>	
DUNN AM	09/01/21	1.50	ADDRESS STATE LICENSING ISSUES (1.5).
DUNN AM	09/01/21	1.00	PARTICIPATE ON STANDING LICENSING CALL (1.0).
DUNN AM	09/02/21	0.50	CALL WITH SKADDEN TEAM AND CONSULTANT RE: LICENSING STATE LICENSE APPLICATIONS (0.3); CALL WITH M. FLORENCE RE: SAME (0.2).
DUNN AM	09/07/21	1.10	REVIEW AND RESPOND TO CORRESPONDENCE RE: STATE LICENSING (1.1).
DUNN AM	09/09/21	0.50	PARTICIPATE ON CALL WITH CO-COUNSEL RE: STATE LICENSING QUESTIONS (0.5).
DUNN AM	09/13/21	0.30	PARTICIPATE ON CALL WITH CO-COUNSEL RE: STATE LICENSING REQUIREMENTS (0.3).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates****ATTORNEY WORK PRODUCT****PRIVILEGED AND CONFIDENTIAL**

DUNN AM	09/15/21	1.00	PARTICIPATE ON CALL WITH CO-COUNSEL RE: LICENSING ISSUES (1.0).
DUNN AM	09/15/21	1.60	REVIEW AND RESPOND TO CORRESPONDENCE RE: LICENSING ISSUES (1.6).
DUNN AM	09/18/21	1.00	REVIEW AND RESPOND TO CORRESPONDENCE RE: LICENSING ISSUES (1.0).
DUNN AM	09/23/21	0.80	REVISE DOCUMENTS RE: LICENSING (0.8).
DUNN AM	09/27/21	1.10	DRAFT CORRESPONDENCE RE: LICENSING ISSUES (1.1).
DUNN AM	09/27/21	0.40	PARTICIPATE ON CALL WITH CLIENT RE: LICENSING QUESTIONS (0.4).
DUNN AM	09/28/21	3.30	REVIEW AND REVISE MEMORANDUM RE: REGULATORY PROCEDURES (3.3).
DUNN AM	09/30/21	0.50	RESPOND TO CORRESPONDENCE RE: LICENSING ISSUES (0.5).
DUNN AM	09/30/21	3.30	REVIEW AND REVISE RESEARCH MEMORANDUM (3.3).
		<b>17.90</b>	
<b>Total Counsel</b>		<b>17.90</b>	
CHAN AH	09/26/21	1.70	REVISE INFORMED CONSENT FORM (1.7).
		<b>1.70</b>	
HELLMAN E	09/01/21	0.90	PARTICIPATE IN CALL WITH CLIENT AND CONSULTANT RE: LICENSING (0.9).
HELLMAN E	09/01/21	0.10	CONFER WITH A. DUNN RE: LICENSING (0.1).
HELLMAN E	09/01/21	2.00	DRAFT FOLLOW-UP MATERIALS RE: LICENSING (2.0).
HELLMAN E	09/03/21	0.50	REVISE MATERIAL RE: LICENSING (0.5).
HELLMAN E	09/07/21	0.30	COORDINATE RE: MEETING ON LICENSING (0.3).
HELLMAN E	09/09/21	4.80	RESEARCH AND DRAFT STATEMENTS RE: LICENSING ISSUES (4.8).
HELLMAN E	09/09/21	0.30	CONFER WITH SKADDEN TEAM LICENSING (0.3).

Skadden, Arps, Slate, Meagher &amp; Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

HELLMAN E	09/10/21	0.20	REVISE AND CIRCULATE RESPONSE RE: LICENSING QUESTION (0.2).
HELLMAN E	09/22/21	0.30	DRAFT SUMMARY POINTS RE: LICENSING CALL(0.3).
HELLMAN E	09/22/21	0.70	CALL WITH CLIENT AND CONSULTANT RE: LICENSING (0.7).
HELLMAN E	09/23/21	0.10	CORRESPOND RE: LICENSING ISSUE (0.1).
HELLMAN E	09/27/21	0.50	IDENTIFY MATERIALS RE: CLIENT QUESTIONS (0.5).
HELLMAN E	09/29/21	0.70	ATTEND TEAM MEETING RE: LICENSING (0.2); CORRESPOND RE: SAME (0.5).
		<b>11.40</b>	
<b>Total Associate</b>		<b>13.10</b>	
<b>MATTER TOTAL</b>		<b><u>76.60</u></b>	

Purdue Pharma L.P. Bill Date: 11/03/21  
Bankruptcy Related Litigation and Regulatory Issues Bill Number: 1871284

NAME	DATE	HOURS	DESCRIPTION
BRAGG JL	09/01/21	0.70	CONFER WITH CO-COUNSEL REGARDING KERP RELATED ISSUES (0.7).
BRAGG JL	09/02/21	0.50	CONFER WITH CO-COUNSEL REGARDING KERP REVIEW (0.5).
BRAGG JL	09/03/21	3.00	REVIEW AND ANALYSIS OF KERP ISSUES (1.4); CONFER WITH CO-COUNSEL RE: KERP ISSUES (0.5); CALL WITH CO-COUNSEL RE: KERP COMMUNICATION (0.6); CONFER WITH CLIENT RE: KERP REVIEW (0.5).
BRAGG JL	09/04/21	2.50	REVIEW AND EDIT KERP LETTER (0.7); REVIEW AND EDIT KERP ANALYSIS (1.8).
BRAGG JL	09/06/21	1.90	ATTENTION TO KERP REVIEW (1.9).
BRAGG JL	09/07/21	2.60	CONFER WITH CO-COUNSEL RE: KERP REVIEW (1.5); CONFER WITH CO-COUNSEL RE: REPOSITORY ISSUES (0.5); ATTENTION TO KERP ISSUES (0.6).
BRAGG JL	09/09/21	4.10	CONFER WITH CLIENT RE: REGULATORY REPORTING ISSUES (0.6); KERP REVIEW (2.0); CONFER WITH CLIENT RE: CLINICAL DATA SHARING ISSUES (1.0); CONFER WITH CO-COUNSEL RE: KERP ISSUES (0.5).
BRAGG JL	09/10/21	4.00	REVIEW AND ANALYSIS OF KERP ISSUES (4.0).
BRAGG JL	09/11/21	1.70	CONFER WITH CO-COUNSEL REGARDING KERP ISSUES (0.5); REVIEW AND ANALYSIS OF KERP MATERIALS (1.2).
BRAGG JL	09/12/21	5.50	REVIEW AND EDIT KERP MATERIALS (5.5).
BRAGG JL	09/13/21	8.10	REVIEW AND ANALYSIS OF KERP MATERIALS (4.0); REVIEW AND ANALYSIS OF CUSTOMER SERVICE MATERIALS (1.8); CONFER WITH CO-COUNSEL RE: COMPLIANCE REVIEW ISSUES (0.6); REVIEW SPECIAL COMMITTEE MATERIALS (0.5); ATTEND SPECIAL COMMITTEE MEETING (1.2).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

BRAGG JL	09/14/21	5.10	REVIEW AND EDIT KERP MATERIALS (3.7); CALL WITH CO-COUNSEL RE: CUSTOMER SERVICE ISSUES (1.0); CALL WITH CO-COUNSEL RE: KERP ISSUES (0.4).
BRAGG JL	09/15/21	6.00	REVIEW AND ANALYZE KERP MATERIALS (5.0); CALL WITH CO-COUNSEL RE: KERP (1.0).
BRAGG JL	09/16/21	1.00	CONFER WITH CLIENT RE: CLAIMS REGULATORY ISSUES (1.0).
BRAGG JL	09/16/21	6.00	REVIEW AND EDIT KERP MATERIALS (6.0).
BRAGG JL	09/17/21	4.80	REVIEW AND EDIT KERP MATERIALS (3.5); CONFER WITH CO-COUNSEL RE: CUSTOMER SERVICE MATERIALS (1.3).
BRAGG JL	09/21/21	2.50	CONFER WITH CO-COUNSEL RE: KERP ISSUES (0.5); REVIEW AND ANALYSIS OF CUSTOMER SERVICE MATERIALS (2.0).
BRAGG JL	09/22/21	3.10	CONFER WITH CO-COUNSEL RE: CUSTOMER SERVICE ISSUES (0.5); CONFER WITH CLIENT RE: CUSTOMER SERVICE ISSUES (1.1); REVIEW AND ANALYSIS OF CUSTOMER SERVICE ISSUES (1.5).
BRAGG JL	09/23/21	7.40	ATTENTION TO CUSTOMER SERVICES MATTERS (4.0); CALL RE: KERP ISSUES (0.7); PREPARE FOR SPECIAL COMMITTEE MEETING (1.2); ATTEND SPECIAL COMMITTEE MEETING (1.5).
BRAGG JL	09/24/21	5.00	REVIEW AND ANALYSIS OF CUSTOMER SERVICE ISSUES (5.0).
BRAGG JL	09/25/21	5.90	REVIEW AND ANALYSIS OF CUSTOMER SERVICE MATERIALS (5.0); CONFER WITH CO-COUNSEL REGARDING CUSTOMER SERVICE ISSUES (0.9).
BRAGG JL	09/26/21	6.40	REVIEW AND ANALYSIS OF CUSTOMER SERVICE MATERIALS (2.5); CONFER WITH CO-COUNSEL RE: CUSTOMER SERVICE ISSUES (1.0); REVIEW AND ANALYSIS OF PRIVILEGE ISSUES (2.9).
BRAGG JL	09/27/21	5.80	CALL WITH CO-COUNSEL RE: CUSTOMER SERVICE ISSUES (1.6); REVIEW AND ANALYSIS OF CUSTOMER SERVICE ISSUES (3.0); CALLS WITH CLIENT RE: CUSTOMER SERVICE ISSUES (1.2).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

BRAGG JL	09/28/21	5.80	CALL WITH CO-COUNSEL RE: CUSTOMER SERVICE ISSUES (1.6); REVIEW AND ANALYSIS OF CUSTOMER SERVICE ISSUES (3.0); CALLS WITH CLIENT RE: CUSTOMER SERVICE ISSUES (1.2).
BRAGG JL	09/28/21	2.00	REVIEW AND EDIT SUBMISSION (2.0).
<b>101.40</b>			
FITZGERALD P	09/01/21	3.70	REVIEW MATERIALS (3.7).
FITZGERALD P	09/02/21	0.40	CONFER WITH J. BRAGG REGARDING PROCESS MOVING FORWARD (0.4).
FITZGERALD P	09/03/21	0.60	COORDINATION CALL REGARDING KERP PROCESS (0.6).
FITZGERALD P	09/04/21	0.10	REVIEW DRAFT LETTER (0.1).
FITZGERALD P	09/05/21	2.10	REVIEW AND EDIT DRAFT MATERIALS (2.1).
FITZGERALD P	09/06/21	0.80	REVIEW DRAFT SUBMISSION FOR FACTUAL ACCURACY (0.8).
FITZGERALD P	09/08/21	0.70	REVIEW AND EDIT DRAFTS (0.2); COORDINATION AND EDITING CALL WITH SKADDEN TEAM TO STANDARDIZE FORMAT AND APPROACH (0.5).
FITZGERALD P	09/09/21	1.70	REVIEW AND EDIT DRAFT FILING FOR ACCURACY (0.6); REVIEW AND EDIT DRAFT SUMMARY DOCUMENT (0.3); UPDATE WITH M. FLORENCE (0.3); SKADDEN TEAM UPDATE ON PROCESS AND PROTOCOLS (0.5).
FITZGERALD P	09/10/21	0.40	CONFER WITH SKADDEN AND CO-COUNSEL REGARDING INQUIRY (0.4).
FITZGERALD P	09/10/21	3.70	REVIEW AND EDIT KERP MATERIALS (2.4); TEAM UPDATE ON KERP WORKSTREAM STATUS (0.9); COORDINATION CALL WITH OUTSIDE COUNSEL AND SKADDEN REGARDING KERP PROCESS (0.4).
FITZGERALD P	09/11/21	0.70	REVIEW AND COMMENT ON DRAFT KERP PRESENTATION (0.7).
FITZGERALD P	09/12/21	1.50	EDIT DRAFT NARRATIVES REGARDING KERP (1.5).
FITZGERALD P	09/13/21	5.30	REVIEW MATERIALS AND DRAFT KERP SUMMARIES (3.7); UPDATE WITH J. ADAMS (0.2); UPDATE WITH M. FLORENCE (0.2); PARTICIPATE IN SPECIAL COMMITTEE CALL (1.2).

## Skadden, Arps, Slate, Meagher &amp; Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FITZGERALD P	09/14/21	3.00	REVIEW AND EDIT KERP SUMMARIES (2.7); PARTICIPATE IN PART OF UPDATE WITH M. KESSELMAN, R. SILBERT AND SKADDEN/DECHERT TEAMS (0.3).
FITZGERALD P	09/15/21	2.10	COORDINATION CALL WITH SKADDEN AND OUTSIDE COUNSEL (0.8); INTERNAL SKADDEN COORDINATION CALL (0.2); REVIEW DRAFT NARRATIVES (1.1).
FITZGERALD P	09/16/21	2.20	REVIEW AND COMMENT ON DRAFT KERP SUMMARY (2.2).
FITZGERALD P	09/17/21	3.10	REVIEW AND FINALIZE KERP REPORT (3.1).
FITZGERALD P	09/21/21	0.30	PORTION OF INTERNAL SKADDEN CALL REGARDING KERP PROCESS (0.3).
FITZGERALD P	09/21/21	0.30	ATTENTION TO COMPLIANCE MATTERS (0.3).
FITZGERALD P	09/22/21	1.70	UPDATE CALL WITH J. BRAGG AND M. FLORENCE (0.2); CALL WITH CO-COUNSEL AND SKADDEN (1.5).
FITZGERALD P	09/23/21	0.20	REVIEW AND EDIT DRAFT OF CHRONOLOGY (0.2).
FITZGERALD P	09/23/21	3.30	REVIEW DRAFT PRESENTATION AND FOLLOW-UP (0.5); CALL IN ADVANCE OF SPECIAL COMMITTEE MEETING WITH OUTSIDE COUNSEL AND SKADDEN TEAM (0.4); INTERNAL SKADDEN CALL REGARDING EDITS TO DRAFT OUTSIDE COUNSEL PRESENTATION (0.5); REVIEW CHRONOLOGY (0.2); PARTICIPATE IN SPECIAL COMMITTEE MEETING (1.7).
FITZGERALD P	09/23/21	0.30	UPDATE CALL WITH SKADDEN TEAM AND OUTSIDE COUNSEL RE: BANKRUPTCY LITIGATION ISSUE (0.3).
FITZGERALD P	09/25/21	1.10	REVIEW MATERIALS AND DRAFT RESPONSES (1.1).
FITZGERALD P	09/26/21	0.20	REVIEW DRAFT COMPLIANCE SUBMISSION (0.2).
FITZGERALD P	09/27/21	0.10	REVIEW DRAFT MATERIALS (0.1).
FITZGERALD P	09/28/21	1.60	PARTICIPATE IN SPECIAL COMMITTEE MEETING (1.6).
FITZGERALD P	09/28/21	0.50	REVIEW DRAFT SUBMISSION (0.1); UPDATE CALL WITH CO-COUNSEL AND SKADDEN TEAMS (0.4).
FITZGERALD P	09/29/21	0.20	REVIEW SUBMISSION (0.2).

FITZGERALD P	09/29/21	0.40	REVIEW MATERIALS REGARDING KERP APPLICANTS (0.4).
		<b>42.30</b>	
FLORENCE MP	09/01/21	2.10	ATTEND BANKRUPTCY HEARING (1.8); CORRESPOND WITH CO-COUNSEL RE: SAME (0.3).
FLORENCE MP	09/02/21	1.20	ATTEND BOARD MEETING (1.2).
FLORENCE MP	09/03/21	0.20	REVIEW DRAFT SUMMARY RE: KERP PROCESS (0.2).
FLORENCE MP	09/04/21	0.50	CORRESPOND WITH CLIENT AND CO-COUNSEL RE: KERP PROCESS (0.5).
FLORENCE MP	09/05/21	0.40	REVIEW AND COMMENT ON DRAFT NARRATIVE (0.4).
FLORENCE MP	09/06/21	0.20	CONFER WITH J. BRAGG RE: KERP PROCESS (0.2).
FLORENCE MP	09/07/21	0.50	REVIEW DRAFT NARRATIVE RE: KERP PROCESS (0.3); CORRESPOND WITH CO-COUNSEL RE: DOCUMENT REPOSITORY (0.2).
FLORENCE MP	09/08/21	3.80	CONFERENCE CALLS WITH SKADDEN TEAM RE: KERP PROCESS (1.2); REVIEW AND EDIT DRAFT NARRATIVES RE: SAME (2.1); CONFER WITH R. ALEALI RE: SAME (0.3); CONFER WITH P. FITZGERALD RE: SAME (0.2).
FLORENCE MP	09/09/21	4.40	REVIEW DRAFT KEIP REPLY BRIEF (0.2); CONFER WITH J. BRAGG RE: KERP PROCESS (0.3); CORRESPOND WITH SKADDEN TEAM RE: SAME (0.8); CONFER WITH M. KESSELMAN RE: SAME (0.4); FOLLOW UP WITH P. FITZGERALD RE: SAME (0.3); CORRESPOND WITH SKADDEN TEAM AND CO-COUNSEL RE: SAME (0.2); CONFER WITH SKADDEN TEAM RE: SAME (0.5); REVIEW AND EDIT DRAFT KERP NARRATIVES (1.6); CORRESPOND WITH CLIENT AND CO-COUNSEL RE: BANKRUPTCY APPEAL PROCESS (0.1).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FLORENCE MP	09/10/21	3.90	PARTICIPATE IN CALL WITH CLIENT AND CO-COUNSEL RE: BANKRUPTCY DISCOVERY (0.5); CONFER WITH CLIENT AND CO-COUNSEL RE: COMPLIANCE REVIEW (0.6); CONFER WITH R. ALEALI RE: KERP PROCESS (0.2); CONFER WITH SKADDEN TEAM RE: SAME (0.7); CORRESPOND WITH CO-COUNSEL RE: SAME (0.8); REVISE DRAFT ANALYSIS RE: KERP REVIEW (0.7); PARTICIPATE IN CALL WITH CO-COUNSEL RE: SAME (0.4).
FLORENCE MP	09/11/21	0.70	REVIEW DRAFT SLIDE DECK RE: KERP PROCESS (0.2); REVIEW AND EDIT DRAFT NARRATIVES RE: KERP REVIEW (0.5).
FLORENCE MP	09/12/21	0.60	REVIEW AND EDIT DRAFT NARRATIVES RE: KERP REVIEW (0.6).
FLORENCE MP	09/13/21	5.70	ATTEND BANKRUPTCY OMNIBUS HEARING (3.7); CONFER WITH P. FITZGERALD RE: KERP PROCESS (0.2); ATTEND SPECIAL COMMITTEE MEETING (1.2); REVIEW AND EDIT DRAFT MATERIALS RE: KERP REVIEW (0.6).
FLORENCE MP	09/14/21	5.20	CORRESPOND WITH SKADDEN TEAM RE: KERP REVIEW (0.8); REVIEW AND EDIT DRAFT NARRATIVES RE: KERP REVIEW (3.2); CONFER WITH J. BRAGG AND CO-COUNSEL RE: SAME (0.4); CONFER WITH CO-COUNSEL AND CLIENT RE: CUSTOMER SERVICE REVIEW (0.8).
FLORENCE MP	09/15/21	1.80	CALL WITH OUTSIDE COUNSEL RE: KERP (1.0); REVIEW AND EDIT DRAFT KERP NARRATIVES (0.8).
FLORENCE MP	09/16/21	2.40	REVIEW AND EDIT KERP NARRATIVES (2.4).
FLORENCE MP	09/17/21	2.40	CORRESPOND WITH CO-COUNSEL RE: KERP PROCESS (0.4); REVIEW AND EDIT DRAFT NARRATIVES (0.2); CORRESPOND WITH CO-COUNSEL RE: SAME (0.5); CONFER WITH CLIENT AND CO-COUNSEL RE: BANKRUPTCY PROCESS (1.2); CONFER WITH R. ALEALI RE: SAME (0.1).
FLORENCE MP	09/19/21	0.50	REVIEW BANKRUPTCY HEARING TRANSCRIPT (0.5).
FLORENCE MP	09/20/21	0.50	RESPOND TO QUESTIONS RE: COMPLIANCE REVIEW (0.5).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**

ATTORNEY WORK PRODUCT

**PRIVILEGED AND CONFIDENTIAL**

FLORENCE MP	09/21/21	1.20	PARTICIPATE IN CALL WITH SKADDEN TEAM RE: KERP PROCESS (0.9); CORRESPOND WITH SKADDEN TEAM RE: COMPLIANCE REVIEW (0.1); REVIEW APPEAL BRIEFS (0.2).
FLORENCE MP	09/22/21	2.30	CONFER WITH CLIENT AND CO-COUNSEL RE: COMPLIANCE REVIEW (0.6); PARTICIPATE IN CALL WITH CLIENT RE: SAME (1.5); CONFER WITH J. BRAGG AND E. BERRY RE: FOLLOW UP FROM CALL (0.2).
FLORENCE MP	09/23/21	4.80	REVIEW AND EDIT DECK RE: KERP PROCESS (0.9); CONFER WITH CO-COUNSEL RE: KERP PROCESS (0.4); CONFER WITH SKADDEN TEAM RE: SAME (0.5); CONFER WITH CO-COUNSEL RE: DRAFT UCC COMPLAINT (0.4); PREPARE FOR SPECIAL COMMITTEE MEETING; PARTICIPATE IN SAME (2.3); CORRESPOND WITH CO-COUNSEL RE: COMPLIANCE REVIEW (0.3).
FLORENCE MP	09/24/21	1.20	CONFER WITH J. BRAGG (0.2); REVIEW DRAFT BANKRUPTCY CALENDAR (0.4); PARTICIPATE IN CALL WITH CLIENT RE: COMPLIANCE REVIEW (0.5); FOLLOW UP WITH J. BRAGG AND E. BERRY RE: SAME (0.1).
FLORENCE MP	09/25/21	1.00	REVIEW AND EDIT MATERIALS RE: COMPLIANCE REVIEW (1.0).
FLORENCE MP	09/26/21	0.70	REVIEW RESPONSES RE: COMPLIANCE REVIEW (0.4); CONFER WITH J. BRAGG RE: SAME (0.3).
FLORENCE MP	09/27/21	0.20	PARTICIPATE IN CALL WITH CO-COUNSEL RE: COMPLIANCE REVIEW (0.2).
FLORENCE MP	09/28/21	2.60	CORRESPOND WITH SKADDEN TEAM RE: KERP PROCESS (0.2); PARTICIPATE IN CALL WITH CO-COUNSEL RE: COMPLIANCE REVIEW (0.3); REVIEW AND EDIT DRAFT RESPONSE RE: REQUESTS (0.4); ATTEND SPECIAL COMMITTEE MEETING (1.7).
		<b>51.00</b>	
RIDGWAY W	09/01/21	1.00	ANALYZE MATERIALS FOR KEIP/KERP REVIEW (1.0).
RIDGWAY W	09/02/21	2.20	REVISE DRAFT WRITEUP RE: KEIP/KERP (1.5); REVIEW MATERIALS RE: KEIP/KERP (0.7).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

RIDGWAY W	09/03/21	2.00	CONFER WITH OUTSIDE COUNSEL RE: KEIP/KERP MATTERS (0.8); ANALYZE MATERIAL RE: KEIP/KERP REVIEW (1.2).
RIDGWAY W	09/06/21	0.50	REVIEW MATERIALS FOR KEIP/KERP (0.5).
RIDGWAY W	09/07/21	3.90	REVISE KEIP/KERP SUMMARIES (2.1); REVIEW MATERIALS FOR KEIP/KERP ANALYSIS (1.8).
RIDGWAY W	09/08/21	2.00	CONFER WITH SKADDEN TEAM RE: KEIP/KERP PROCESS (0.6); REVISE WRITEUP RE: KEIP/KERP INDIVIDUALS (1.4).
RIDGWAY W	09/09/21	1.60	CONFER WITH SKADDEN TEAM RE: KEIP/KERP PROCESS (0.5); CONFER WITH C. HOUSTON RE: ANALYSIS OF CANDIDATES (0.3); REVISE KEIP/KERP WRITEUP (0.8).
RIDGWAY W	09/10/21	3.80	CONFER WITH SKADDEN TEAM RE: LEGAL STRATEGY AND KERP/KEIP REVIEW (1.1); REVISE DRAFT MEMORANDA RE: KERP/KEIP REVIEW (2.3); CONFER WITH OUTSIDE COUNSEL RE: KERP/KEIP REVIEW (0.4).
RIDGWAY W	09/11/21	2.20	REVISE KEIP/KERP MATERIALS (1.7); CONFER WITH SKADDEN TEAM RE: KEIP/KERP REVIEW (0.5).
RIDGWAY W	09/12/21	1.90	REVISE MATERIALS FOR KEIP/KERP REVIEW (1.9).
RIDGWAY W	09/13/21	4.80	KERP HEARING (1.1); CONFER WITH SKADDEN TEAM RE: KERP REVIEW (0.7); PREPARE AND REVISE KERP MATERIALS (2.5); AND REVISE MATERIALS RE: KERP BACKGROUND (0.5).
RIDGWAY W	09/14/21	5.30	CONFER WITH SKADDEN TEAM RE: KERP/KEIP REVIEW (1.1); ANALYZE AND REVISE KERP/KEIP MATERIALS (4.2).
RIDGWAY W	09/15/21	4.00	CONFER WITH SKADDEN TEAM AND OUTSIDE COUNSEL RE: KERP REVIEW PROCESS (0.6); COMMUNICATE WITH OUTSIDE COUNSEL RE: KERP REVIEW PROCESS (0.5); REVIEW AND REVISE MATERIALS RE: KERP REVIEW (2.9).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**

ATTORNEY WORK PRODUCT

**PRIVILEGED AND CONFIDENTIAL**

RIDGWAY W	09/16/21	6.10	REVIEW AND REVISE KERP/KEIP REVIEW MATERIALS (4.7); CONFER WITH SKADDEN TEAM RE: KERP/KEIP STRATEGY (0.6); CONFER WITH W. BEJAN RE: KERP REVIEW (0.2); CONFER WITH C. HOUSTON RE: KERP/KEIP REVIEW (0.6).
RIDGWAY W	09/17/21	5.00	REVIEW AND REVISE KERP/KEIP MATERIALS (4.5); CONFER WITH SKADDEN TEAM RE: KERP/KEIP REVIEW (0.5).
RIDGWAY W	09/21/21	1.10	CONFER WITH SKADDEN TEAM RE: KERP/KEIP REVIEW (0.9); CONFER WITH OUTSIDE COUNSEL RE: KERP MATERIALS (0.2).
RIDGWAY W	09/23/21	4.00	CONFER WITH SKADDEN TEAM AND OUTSIDE COUNSEL RE: KERP REVIEW (0.5); REVIEW AND REVISE MATERIALS RE: KERP REVIEW (1.0); REVIEW MATERIALS FOR PRESENTATION (0.7); PARTICIPATE IN MEETING RE: KERP REVIEW (1.8).
RIDGWAY W	09/28/21	2.30	PREPARE FOR MEETING RE: KERP/KEIP REVIEW (0.6); PARTICIPATE IN MEETING RE: KERP/KEIP REVIEW (1.7).
RIDGWAY W	09/29/21	0.40	CONFER WITH OUTSIDE COUNSEL RE: KERP/KEIP REVIEW (0.4).
<b>54.10</b>			
<b>Total Partner</b>		<b>248.80</b>	
BEJAN WA	09/02/21	0.70	DRAFT ISSUE AND EMPLOYEE SUMMARIES RE: KEIP/KERP REVIEW (0.7).
BEJAN WA	09/06/21	1.70	DRAFT ISSUE AND EMPLOYEE SUMMARIES RE: KEIP/KERP REVIEW (1.7).
BEJAN WA	09/07/21	6.70	DRAFT ISSUE AND EMPLOYEE SUMMARIES RE: KEIP/KERP REVIEW (6.7).
BEJAN WA	09/07/21	0.30	CALL WITH SKADDEN TEAM RE: KEIP/KERP REVIEW (0.3).
BEJAN WA	09/08/21	0.50	CALL WITH SKADDEN TEAM RE: KEIP/KERP REVIEW (0.5).
BEJAN WA	09/08/21	1.80	DRAFT ISSUE AND EMPLOYEE SUMMARIES RE: KEIP/KERP REVIEW (1.8).
BEJAN WA	09/09/21	1.90	DRAFT ISSUE AND EMPLOYEE SUMMARIES RE: KEIP/KERP REVIEW (1.9).
BEJAN WA	09/10/21	2.90	DRAFT ISSUE AND EMPLOYEE SUMMARIES RE: KEIP/KERP REVIEW (2.9).

## Skadden, Arps, Slate, Meagher &amp; Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

BEJAN WA	09/10/21	0.10	CALL WITH SKADDEN TEAM RE: KEIP/KERP REVIEW (0.1).
BEJAN WA	09/11/21	0.80	DRAFT ISSUE AND EMPLOYEE SUMMARIES RE: KEIP/KERP REVIEW (0.8).
BEJAN WA	09/13/21	5.20	DRAFT ISSUE AND EMPLOYEE SUMMARIES RE: KEIP/KERP REVIEW (5.2).
BEJAN WA	09/13/21	0.60	CALL WITH SKADDEN TEAM RE: KEIP/KERP REVIEW (0.6).
BEJAN WA	09/14/21	5.20	DRAFT ISSUE AND EMPLOYEE SUMMARIES RE: KEIP/KERP REVIEW (5.2).
BEJAN WA	09/15/21	7.80	DRAFT ISSUE AND EMPLOYEE SUMMARIES RE: KEIP/KERP REVIEW (7.8).
BEJAN WA	09/23/21	1.50	REVIEW OUTSIDE COUNSEL SPECIAL COMMITTEE PRESENTATION (1.5).
		<b>37.70</b>	
BERRY EL	09/01/21	4.00	REVIEW AND IDENTIFY RELEVANT WORK PRODUCT (3.8); CALL WITH E. HELLMAN RE: WORK PROJECT (0.2).
BERRY EL	09/02/21	3.70	CONTINUE TO REVIEW AND IDENTIFY RELEVANT WORK PRODUCT (0.8); BEGIN TO DRAFT SUMMARIES OF RELEVANT WORK PRODUCT (2.9).
BERRY EL	09/03/21	2.90	BEGIN TO DRAFT SUMMARIES OF RELEVANT WORK PRODUCT (2.9).
BERRY EL	09/12/21	2.20	DRAFT SUMMARIES RE: KERP REVIEW (2.2).
BERRY EL	09/13/21	8.10	CONTINUE TO DRAFT SUMMARIES RE: KERP REVIEW (7.5); CALL WITH SKADDEN TEAM RE: SUMMARIES (0.6).
BERRY EL	09/14/21	8.20	CONTINUE TO DRAFT SUMMARIES RE: KERP REVIEW (8.2).
BERRY EL	09/14/21	1.30	DRAFT CHRONOLOGY OF COMPLIANCE REVIEW (0.5); CALL WITH CO-COUNSEL AND SKADDEN RE: COMPLIANCE REVIEW (0.8).
BERRY EL	09/15/21	7.90	CONTINUE TO DRAFT SUMMARIES RE: KERP REVIEW (7.9).
BERRY EL	09/16/21	3.00	CONTINUE TO DRAFT SUMMARIES RE: KERP REVIEW (3.0).
BERRY EL	09/17/21	1.30	DRAFT CHRONOLOGY OF COMPLIANCE REVIEW (1.3).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates****ATTORNEY WORK PRODUCT****PRIVILEGED AND CONFIDENTIAL**

BERRY EL	09/17/21	0.50	CONTINUE TO DRAFT SUMMARIES RE: KERP REVIEW (0.5).
BERRY EL	09/19/21	2.00	DRAFT CHRONOLOGY RE: COMPLIANCE REVIEW (2.0).
BERRY EL	09/20/21	1.40	CREATE AND REVIEW CHRONOLOGY AND BINDER RE: COMPLIANCE REVIEW (1.4).
BERRY EL	09/21/21	1.00	COMMUNICATE IN FIRM RE: COMPLIANCE REVIEW (1.0).
BERRY EL	09/22/21	2.90	PARTICIPATE IN CALLS RE: COMPLIANCE REVIEW (1.0); AND DRAFT WORK PRODUCT RE: SAME (1.9).
BERRY EL	09/23/21	6.80	BEGIN TO DRAFT SUMMARY RE: COMPLIANCE REVIEW (3.8); REVIEW ASSOCIATED DOCUMENTS (3.8).
BERRY EL	09/24/21	5.40	CONTINUE TO DRAFT SUMMARY RE: COMPLIANCE REVIEW (3.4); AND REVIEW ASSOCIATED DOCUMENTS (2.0).
BERRY EL	09/25/21	6.00	DRAFT SUMMARY OF COMPLIANCE REVIEW (3.2); AND REVIEW MATERIALS RE: SAME (2.0); CALL WITH DECHERT RE: COMPLIANCE REVIEW (0.8).
BERRY EL	09/26/21	4.20	CONTINUE TO DRAFT SUMMARY OF COMPLIANCE REVIEW (3.2) AND REVIEW MATERIALS RE: SAME (1.0).
BERRY EL	09/27/21	2.90	DRAFT LOG OF MATERIALS RE: PRIVILEGE REVIEW (1.8); CALL WITH CO-COUNSEL RE: COMPLIANCE REVIEW (0.7); CALL WITH CO-COUNSEL, J. BRAGG, AND EMPLOYEE RE: COMPLIANCE REVIEW (0.4).
BERRY EL	09/28/21	5.00	CALL WITH RE: COMPLIANCE REVIEW (1.1); REVIEW AND ANALYZE DOCUMENTS RE: COMPLIANCE REVIEW (3.0) CALL RE: COMPLIANCE REVIEW (0.5); CALL WITH CO-COUNSEL AND SKADDEN RE: COMPLIANCE REVIEW (0.4).
BERRY EL	09/30/21	0.30	CALL WITH CO-COUNSEL RE: COMPLIANCE REVIEW (0.3).
		<b>81.00</b>	
CHAN AH	09/01/21	5.90	DRAFT SUMMARIES RE: KERP REVIEW (5.9).
CHAN AH	09/02/21	3.00	REVIEW MATERIALS FOR MEMO (3.0).
CHAN AH	09/03/21	3.70	DRAFT KERP/KEIP MEMO (3.7).

## Skadden, Arps, Slate, Meagher &amp; Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

CHAN AH	09/07/21	0.30	CONFER ON NEXT STEPS (0.3).
CHAN AH	09/07/21	7.70	DRAFT MEMO RE: KERP REVIEW (7.7).
CHAN AH	09/08/21	3.20	REVISE ISSUE SUMMARIES AND MEMO RE: KERP (3.2).
CHAN AH	09/08/21	0.50	CONFER ON ISSUE SUMMARIES (0.5).
CHAN AH	09/09/21	4.90	REVISE ISSUE SUMMARIES (4.9).
CHAN AH	09/10/21	0.20	CONFER ON MEMO (0.2).
CHAN AH	09/10/21	4.40	DRAFT MEMO RE: KERP REVIEW (4.4).
CHAN AH	09/11/21	3.10	DRAFT MEMO RE: KERP REVIEW (3.1).
CHAN AH	09/13/21	12.50	DRAFT MEMO RE: KERP REVIEW (12.5).
CHAN AH	09/13/21	0.60	CONFER ON NEXT STEPS RE: MEMOS AND ISSUE SUMMARIES (0.6).
CHAN AH	09/14/21	10.20	REVISE MEMOS RE: KERP REVIEW (10.2).
CHAN AH	09/15/21	3.10	REVISE MEMOS RE: KERP REVIEW (3.1).
CHAN AH	09/16/21	3.70	DRAFT MEMOS RE: KERP REVIEW (3.7).
CHAN AH	09/17/21	2.50	REVISE MEMO RE: KERP REVIEW (2.5).
		<b>69.50</b>	
HELLMAN E	09/01/21	5.50	COLLECT DOCUMENTS RE: KERP REVIEW (5.5).
HELLMAN E	09/02/21	2.80	REVIEW MATERIAL RE: KERP SUMMARIES (2.8).
HELLMAN E	09/02/21	4.90	COLLECT AND COORDINATE WORK PRODUCT RE: KERP PROJECT (4.9).
HELLMAN E	09/03/21	6.60	COORDINATE COLLECTION OF MATERIALS RE: KERP (0.3); REVIEW MATERIALS RE: KERP (6.3).
HELLMAN E	09/09/21	0.60	REVISE MATERIAL RE: KERP REVIEW (0.6).
HELLMAN E	09/10/21	4.10	RESEARCH AND DRAFT MATERIAL RE: KERP (4.1).
HELLMAN E	09/12/21	4.90	DRAFT AND REVISE MATERIALS RE: KERP (4.9).
HELLMAN E	09/13/21	7.70	DRAFT AND REVISE KERP SUMMARIES (7.7).
HELLMAN E	09/13/21	0.60	CONFER WITH TEAM RE: KERP SUMMARIES (0.6).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

HELLMAN E	09/14/21	11.20	DRAFT AND REVISE KERP SUMMARIES (11.2).
HELLMAN E	09/15/21	7.90	DRAFT AND REVISE MATERIALS RE: KERP (7.9).
HELLMAN E	09/17/21	4.50	REVISE KERP SUMMARIES (4.5).
HELLMAN E	09/23/21	1.90	REVISE MATERIALS RE: KERP (1.9).
		<b>63.20</b>	
HOUSTON CD	09/01/21	6.10	DRAFT SUMMARIES REGARDING KERP (4.2); CONTINUE TO REVIEW DOCUMENTS RELATED TO PERSONNEL (1.9).
HOUSTON CD	09/02/21	4.30	CONTINUE TO DRAFT SUMMARIES REGARDING CERTAIN KERP INDIVIDUALS (4.3).
HOUSTON CD	09/03/21	0.60	REVIEW DOCUMENT REVIEW DATABASE TO AID COLLECTION OF PRIOR WORK PRODUCT (0.6).
HOUSTON CD	09/07/21	6.40	ATTEND CALL WITH TEAM TO DISCUSS NEXT STEPS (0.5); CONTINUE EDITING NARRATIVES RELATED TO KERP (3.3); CONTINUE REVIEWING DOCUMENTS RELATED TO KERP (2.6).
HOUSTON CD	09/08/21	7.90	CONTINUE TO EDIT NARRATIVES RE: KERP (2.4); REVIEW MATERIALS RELATED TO KERP (2.8); ATTEND CALL WITH TEAM TO DISCUSS PROCESS (0.5); BEGIN TO REVIEW MATERIALS RELATED TO KERP (2.2).
HOUSTON CD	09/09/21	3.50	CONTINUE TO DRAFT SUMMARIES REGARDING KERP (1.2); REVIEW DOCUMENTS RELATED TO NON-PRIORITY KERP PARTICIPANTS (1.8); ATTEND CALL WITH TEAM TO DISCUSS KERP PROJECT (0.5).
HOUSTON CD	09/10/21	3.90	ATTEND CALL WITH TEAM TO DISCUSS NEXT STEPS (0.6); REVIEW FILES RELATED TO KERP (3.3).
HOUSTON CD	09/12/21	2.30	REVIEW AND EDIT NARRATIVES RE: KERP (2.3).
HOUSTON CD	09/13/21	7.20	CONTINUE TO EDIT SUMMARIES RE: KERP (2.1); CONTINUE TO EDIT MEMORANDUM RE: KERP (1.9); ATTEND CALL WITH TEAM TO DISCUSS PROJECT (0.6); REVIEW MATERIALS RELATED TO KERP (2.6).

HOUSTON CD	09/14/21	8.40	CONTINUE EDITING SUMMARIES (1.2); COMMUNICATE WITH FIRM PERSONNEL REGARDING STATUS OF KERP PROJECTS AND ASSIGNMENTS (1.4); REVIEW FILES RELATED TO KERP (4.1); REVIEW ASSOCIATE WORK PRODUCT RE: KERP (1.7).
HOUSTON CD	09/15/21	8.60	ATTEND CALLS WITH TEAM TO DISCUSS KERP PROJECT (1.1); CONTINUE DRAFTING NARRATIVES RE: KERP (1.9); REVIEW ASSOCIATE WORK PRODUCT AND BEGIN DRAFTING CONSOLIDATED KERP/KEIP MEMO (5.6).
HOUSTON CD	09/16/21	4.30	CONTINUE TO EDIT CONSOLIDATED MEMO RE: KERP/KEIP PARTICIPANTS (4.3).
HOUSTON CD	09/17/21	4.10	CONTINUE TO EDIT MEMORANDUM RE: KERP/KEIP PARTICIPANTS (4.1).
HOUSTON CD	09/23/21	4.00	ATTEND CALLS WITH TEAM TO DISCUSS KERP PRESENTATION DECK (1.0); EDIT PRESENTATION DECK (3.0).
HOUSTON CD	09/29/21	0.20	REVIEW CORRESPONDENCE RELATED TO ADDITIONAL KERP PARTICIPANTS (0.2).
		<b>71.80</b>	
PAULSON SM	09/01/21	3.30	REVIEW AND ANALYZE ISSUES RE: KERP REVIEW (3.3).
PAULSON SM	09/02/21	3.50	REVIEW AND ANALYZE ISSUES RE: KERP REVIEW (3.5).
PAULSON SM	09/03/21	2.50	REVIEW AND ANALYZE WORK PRODUCT AND DOCUMENTS REGARDING KERP REVIEW(2.5).
PAULSON SM	09/03/21	2.80	DRAFT ANALYSIS OF FACTUAL ISSUES REGARDING DOJ RESOLUTION (2.8).
PAULSON SM	09/04/21	0.40	ANALYZE FACTUAL ISSUES IN CONNECTION WITH KERP/KEIP PLAN (0.4).
PAULSON SM	09/06/21	2.10	ANALYZE FACTUAL ISSUES IN CONNECTION WITH KERP/KEIP PLAN (2.1).
PAULSON SM	09/07/21	5.40	ANALYZE FACTUAL ISSUES IN CONNECTION WITH KERP/KEIP PLAN (5.4).
PAULSON SM	09/08/21	2.30	ANALYZE FACTUAL ISSUES IN CONNECTION WITH KERP/KEIP PLAN (2.3).

PAULSON SM	09/09/21	0.90	ANALYZE FACTUAL ISSUES IN CONNECTION WITH KERP/KEIP PLAN (0.9).
PAULSON SM	09/10/21	2.20	ANALYZE FACTUAL ISSUES IN CONNECTION WITH KERP/KEIP PLAN (2.2).
PAULSON SM	09/11/21	4.20	ANALYZE FACTUAL ISSUES IN CONNECTION WITH KERP/KEIP PLAN (4.2).
PAULSON SM	09/12/21	3.30	ANALYZE FACTUAL ISSUES IN CONNECTION WITH KERP/KEIP PLAN (3.3).
PAULSON SM	09/13/21	6.10	ANALYZE FACTUAL ISSUES IN CONNECTION WITH KERP/KEIP PLAN (6.1).
PAULSON SM	09/14/21	11.30	REVIEW AND ANALYZE FACTUAL ISSUES IN CONNECTION WITH KERP/KEIP ASSESSMENTS (11.3).
PAULSON SM	09/15/21	9.60	REVIEW AND ANALYZE FACTUAL ISSUES IN CONNECTION WITH KERP/KEIP ASSESSMENTS (9.6).
PAULSON SM	09/16/21	10.20	REVIEW AND ANALYZE FACTUAL ISSUES IN CONNECTION WITH KERP/KEIP ASSESSMENTS (10.2).
PAULSON SM	09/17/21	1.70	ANALYZE FACTUAL ISSUES IN CONNECTION WITH KERP/KEIP PLAN (1.7).
PAULSON SM	09/23/21	0.40	REVIEW BOARD PRESENTATION REGARDING KERP/KEIP PLAN (0.4).
<b>72.20</b>			
<b>Total Associate</b>		<b>395.40</b>	
TERRY WC	09/01/21	3.30	ASSIST CASE TEAM WITH ELECTRONIC DISCOVERY PROJECT RE: COORDINATING COLLECTION, PROCESSING AND TRANSFER OF E-DATA (3.3).
TERRY WC	09/02/21	1.70	ASSIST CASE TEAM WITH ELECTRONIC DISCOVERY PROJECT RE: COORDINATING PROCESSING OF E-DATA BY E-DISCOVERY SERVICE PROVIDER (1.7).
TERRY WC	09/03/21	4.40	ASSIST CASE TEAM WITH ELECTRONIC DISCOVERY PROJECT RE: COORDINATING TRANSFER AND PROCESSING OF E-DATA BY E-DISCOVERY SERVICE PROVIDER (4.4).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

TERRY WC	09/07/21	0.30	ASSIST CASE TEAM WITH ELECTRONIC DISCOVERY PROJECT RE: COORDINATING PROCESSING OF ELECTRONIC FILES BY E-DISCOVERY SERVICES PROVIDER (0.3).
TERRY WC	09/08/21	3.40	ASSIST CASE TEAM WITH ELECTRONIC DISCOVERY PROJECT RE: COORDINATE PROCESSING OF CLIENT E-DATA BY E-DISCOVERY SERVICES PROVIDER (3.4).
TERRY WC	09/09/21	2.70	ASSIST CASE TEAM WITH ELECTRONIC DISCOVERY PROJECT RE: COORDINATING COLLECTION, TRANSFER AND PROCESSING OF E-DATA BY E-DISCOVERY SERVICES PROVIDER (2.7).
TERRY WC	09/10/21	2.40	ASSIST CASE TEAM WITH ELECTRONIC DISCOVERY PROJECT RE: COORDINATE PROCESSING OF E-DATA BY E-DISCOVERY SERVICES PROVIDER (2.4).
		<b>18.20</b>	
<b>Total Client Specialist</b>		<b>18.20</b>	
AZADEH D	09/20/21	5.80	ASSEMBLE CHRONOLOGY BINDER FOR ATTORNEY REVIEW (5.8).
AZADEH D	09/24/21	0.20	ASSEMBLE CHRONOLOGY BINDER FOR ATTORNEY REVIEW (0.2).
		<b>6.00</b>	
DE BOER M	09/02/21	2.30	ORGANIZE EXHIBITS FOR ATTORNEY REVIEW (2.3).
DE BOER M	09/03/21	3.00	ORGANIZE EXHIBITS FOR ATTORNEY REVIEW (3.0).
DE BOER M	09/03/21	1.00	ORGANIZE EXHIBITS FOR ATTORNEY REVIEW (1.0).
		<b>6.30</b>	
FIEBERG WR	09/03/21	0.70	RETRIEVE DOCUMENTS FROM RELATIVITY FOR ATTORNEY REVIEW (0.7).
FIEBERG WR	09/07/21	2.80	RETRIEVE DOCUMENTS FROM RELATIVITY INCLUDING MULTIPLE TEXT SEARCHES (2.8).
FIEBERG WR	09/08/21	1.60	RETRIEVE DOCUMENTS FROM RELATIVITY FOR ATTORNEY REVIEW (1.6).
FIEBERG WR	09/13/21	1.70	ASSEMBLE DOCUMENTS FOR ATTORNEY REVIEW FOR THE KERP/KEIP REQUEST (1.7).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FIEBERG WR	09/14/21	0.80	ASSEMBLE DOCUMENTS FOR ATTORNEY REVIEW FOR THE KEPR/KEIP REQUEST (0.8).
FIEBERG WR	09/15/21	1.20	ASSEMBLE DOCUMENTS FOR ATTORNEY REVIEW FOR THE KERP/KEIP REQUEST (1.2).
FIEBERG WR	09/17/21	5.80	PROOFREAD KEIP/KERP MEMO (5.8).
		<b>14.60</b>	
HOHMANN MJ	09/23/21	3.50	CONFER WITH ATTORNEY RE: PREPARING DRAFT PRIVILEGE LOG RE: CUSTOMER SERVICE REVIEW (0.3); REVIEW MATERIALS SENT BY ATTORNEY AND ADD TO COLLECTION (0.6); PREPARE DRAFT LOG (2.4); SEND DRAFT LOG TO ATTORNEY WITH QUESTIONS AND NOTES (0.2).
HOHMANN MJ	09/24/21	2.50	CONFER WITH ATTORNEY RE: UPDATING ELECTRONIC COLLECTION OF PRIV. LOG MATERIALS AND DOCS TO PRODUCE (0.1); UPDATE ELECTRONIC COLLECTION AND SEND TO ATTORNEY WITH NOTES (0.4); CONFER WITH ATTORNEY RE: DOCUMENT DATE ISSUE AND FURTHER UPDATES TO LOG AND DOCUMENT SET (0.2); CONTINUE TO DRAFT PRIV. DESCRIPTIONS (0.8); REVIEW ADDITIONAL ATTORNEY COMMENTS/INSTRUCTIONS AND BEGIN FURTHER UPDATES TO DOCUMENT COMPILATION AND DRAFT PRIV. LOG PER REQUEST (1.0).

HOHMANN MJ	09/25/21	3.10	COMPLETE DRAFTING PRIV. DESCRIPTIONS IN DRAFT PRIV. LOG AND COMPLETE UPDATES TO COMPILATION PER ATTORNEY INSTRUCTIONS (0.7); DRAFT/ADD NATIVE SLIPSHEETS TO COMPILATION AND SAVE (0.3); COMPARE SPREADSHEETS PER ATTORNEY REQUEST AND SEND INQUIRY TO ATTORNEY RE: PRODUCING NATIVE POWERPOINT (0.2); SEND UPDATED PRIV. LOG AND COMPILATION TO ATTORNEY FOR REVIEW WITH NOTES/QUESTIONS (0.1); COMM. WITH ATTORNEY RE: ADDITIONAL UPDATES FROM TEAM AND PREPARE ADDITIONAL EMAILS AND ATTACHMENTS FOR INCLUSION IN DRAFT LOG AND COMPILATION (0.3); UPDATE DRAFT LOG AND COMPILATION, CONVERT DRAFT REDACtIONS TO BLACK, AND SEND TO ATTORNEY FOR REVIEW WITH NOTES/QUESTIONS (0.8); CONFER WITH ATTORNEY RE: SEALING REDACtIONS AND APPLYING CONFIDENTIALITY STAMP TO COMPILATION PAGES (0.1); REVIEW ADDITIONAL ATTORNEY COMMENTS AND UPDATE DRAFT PRIV. LOG AND COMPILATION (0.3); SAVE/SEND DRAFT LOG AND COMPILATION TO ATTORNEY WITH NOTES (0.2); FILL OUT/SUBMIT REQUEST TO SEAL REDACtIONS (0.1).
HOHMANN MJ	09/26/21	2.70	PREPARE UPDATED VERSION OF COMPILATION WITH SEALED REDACtIONS, APPLY CONFIDENTIALITY STAMPS, AND SAVE/SEND TO ATTORNEY WITH NOTES (0.4); REVIEW ATTORNEY COMMENTS RE: DRAFT PRIV. LOG AND UPDATE COMPILATION (0.3); UPDATE PRIV. LOG AND DOCUMENT DATES PER ATTORNEY INSTRUCTIONS (0.4; PREPARE COLLECTION OF WITHHELD DOCS AND SEND TO ATTORNEY PER REQUEST (0.4); SEND UPDATED PRIV. LOG AND COMPILATION TO ATTORNEY FOR REVIEW (0.1); COMM. WITH ATTORNEY RE: ADDING BATES STAMPS TO COMPILATION AND ADDITIONAL EDITS (0.1); AFFIX BATES STAMPS TO COMPILATION AND SEND TO ATTORNEY FOR REVIEW (0.3); FURTHER UPDATE COMPILATION PER ADDITIONAL ATTORNEY FEEDBACK, AFFIX BATES AND CONFIDENTIALITY STAMPS, AND SAVE/SEND TO ATTORNEY (0.5); UPDATE WITHHELD DOCUMENTS COMPILATION AND SAVE/SEND TO ATTORNEY PER REQUEST (0.2).

11.80

Total Legal Assistant 38.70

MATTER TOTAL 701.10

Purdue Pharma L.P.  
Corporate/Transactional Advice

**Bill Date:** 11/03/21  
**Bill Number:** 1871285

NAME	DATE	HOURS	DESCRIPTION
FLORENCE MP	09/07/21	0.30	CORRESPOND WITH CLIENT RE: FDA REGULATORY REQUIREMENTS (0.2); CORRESPOND WITH CLIENT AND CO-COUNSEL RE: TRANSACTIONAL ISSUE (0.1).
FLORENCE MP	09/08/21	0.20	CORRESPOND WITH CLIENT RE: TRANSACTIONAL ISSUE (0.2).
FLORENCE MP	09/20/21	1.50	REVIEW AND COMMENT ON DRAFT AGREEMENT (0.7); CONFER WITH A. DUNN RE: SAME (0.5); CONFER WITH A. DUNN AND W. RIDGWAY RE: SAME (0.3).
<b>2.00</b>			
MCCONAGHA W	09/01/21	1.50	FINAL EDITS TO AGREEMENT AND DRAFT COVER ANALYSIS (1.5).
MCCONAGHA W	09/01/21	0.50	CORRESPOND RE: TRANSACTIONAL ISSUE (0.5).
MCCONAGHA W	09/02/21	1.00	CALL WITH CO-COUNSEL RE: TRANSACTIONAL ISSUE (1.0).
MCCONAGHA W	09/02/21	0.80	EMAILS AND REVIEW OF DOCUMENTS RELATED TO QUALITY AGREEMENT (0.8).
MCCONAGHA W	09/03/21	1.00	DRAFT AND REVISE MATERIAL RE: TRANSACTIONAL ISSUES (1.0).
MCCONAGHA W	09/03/21	2.80	REVIEW AND REVISE AGREEMENT (2.8).
MCCONAGHA W	09/08/21	1.30	REVIEW UPDATES TO TEMPLATE (1.3).
MCCONAGHA W	09/09/21	1.30	RESEARCH LITIGATION DISCOVERY ISSUES (0.8); CORRESPOND RE: LITIGATION DISCOVERY ISSUES (0.5).
MCCONAGHA W	09/09/21	1.00	CORRESPOND WITH CO-COUNSEL ON REGULATORY TRANSITION ISSUES (1.0).
MCCONAGHA W	09/09/21	0.80	PREPARE FOR AND PARTICIPATE IN CALL WITH TEAM ON DEA EMERGENCE ISSUES (0.8).
MCCONAGHA W	09/09/21	1.50	PREPARE FOR AND PARTICIPATE IN CALLS CO-COUNSEL RELATED TO CLINICAL TRIAL TRANSITION ISSUES (1.5).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**

ATTORNEY WORK PRODUCT

**PRIVILEGED AND CONFIDENTIAL**

MCCONAGHA W	09/10/21	1.50	RESEARCH AND ANALYZE TRANSACTIONAL ISSUES (1.0); CORRESPOND WITH CO-COUNSEL RE: SAME (0.5).
MCCONAGHA W	09/13/21	0.50	EMAILS AND CALLS WITH CO-COUNSEL ON TRANSACTIONAL ISSUES (0.5).
MCCONAGHA W	09/13/21	1.30	ANALYZE TRANSACTIONAL ISSUES (0.8); CORRESPOND WITH CO-COUNSEL RE: SAME (0.5).
MCCONAGHA W	09/14/21	2.00	REVIEW AND REVISE TEMPLATE (1.5); CONFER WITH A. CHAN ON SAME (0.5).
MCCONAGHA W	09/15/21	2.30	DRAFT SLIDE DECK ON REGULATORY ISSUES (2.3).
MCCONAGHA W	09/15/21	0.80	REVIEW QUALITY INVESTIGATION MATERIAL FROM COUNSEL (0.8).
MCCONAGHA W	09/16/21	0.50	CALL WITH CO-COUNSEL RE: TRANSACTIONAL ISSUE (0.5).
MCCONAGHA W	09/16/21	0.80	PREPARE FOR CALL RE: TRANSACTIONAL ISSUES (0.3); PARTICIPATE IN CALL WITH CO-COUNSEL RE: SAME (0.5).
MCCONAGHA W	09/16/21	1.00	REVIEW AND REVISE ISSUES SLIDES (1.0).
MCCONAGHA W	09/26/21	2.80	REVIEW AND REVISE MATERIAL RE: TRANSACTIONAL ISSUE (2.0); DRAFT EMAIL ON SAME FOR CO-COUNSEL (0.8).
MCCONAGHA W	09/28/21	2.80	REVIEW AND REVISE MATERIAL RE: TRANSACTIONAL ISSUE (2.8).
MCCONAGHA W	09/28/21	1.30	REVIEW AND REVISE MEMORANDUM RE: TRANSACTIONAL ISSUE (1.3).
MCCONAGHA W	09/28/21	0.50	ANALYZE REGULATORY ISSUE (0.5).
MCCONAGHA W	09/30/21	2.30	RESEARCH AND DRAFT ANALYSIS RE: REGULATORY ISSUE (2.3).
MCCONAGHA W	09/30/21	0.50	REVIEW UPDATES TO MATERIAL RE: TRANSACTIONAL ISSUES (0.3); AND DRAFT EMAIL RE: SAME (0.5).
MCCONAGHA W	09/30/21	1.30	CALL WITH EXTERNAL PARTY AND DRAFT SUMMARY OF CALL FOR CO-COUNSEL (1.3).
		35.70	
<b>Total Partner</b>		<b>37.70</b>	

CORALLO KC	09/01/21	2.50	REVIEW CLINICAL TRIAL AGREEMENT; PREPARE COMMENTS AND REVISE; CONFER WITH TEAM (2.5).
		2.50	
<b>Total Of Counsel</b>		<b>2.50</b>	
CHAN AH	09/01/21	0.90	REVISE AGREEMENT (0.9).
CHAN AH	09/02/21	3.30	REVIEW QUALITY AGREEMENT (3.3).
CHAN AH	09/02/21	0.50	CONDUCT REGULATORY RESEARCH (0.5).
CHAN AH	09/03/21	3.20	CONDUCT REGULATORY RESEARCH (3.2).
CHAN AH	09/07/21	1.00	REVISE RESEARCH SUMMARY (1.0).
CHAN AH	09/08/21	0.50	REVIEW AGREEMENT MARK-UP (0.5).
CHAN AH	09/08/21	0.10	REVIEW REGULATORY CORRESPONDENCE (0.1).
CHAN AH	09/09/21	0.50	CONFER WITH CLIENT ON NEXT STEPS RE: REGULATORY ISSUE (0.5).
CHAN AH	09/09/21	0.20	PREPARE FOR CALL WITH VENDOR (0.2).
CHAN AH	09/09/21	0.30	CONFER WITH CLIENT AND VENDOR ON NEXT STEPS (0.3).
CHAN AH	09/10/21	2.80	CONDUCT REGULATORY RESEARCH (2.8).
CHAN AH	09/10/21	0.20	CONFER ON REGULATORY RESEARCH (0.2).
CHAN AH	09/20/21	0.40	PARTICIPATE IN CALL WITH EXTERNAL PARTIES RE: REGULATORY ISSUE (0.4).
CHAN AH	09/20/21	0.90	WORK ON FOLLOW-UP FROM CALL (0.9).
CHAN AH	09/20/21	2.50	CONDUCT REGULATORY RESEARCH (2.5).
CHAN AH	09/21/21	2.60	CONDUCT REGULATORY RESEARCH (2.6).
CHAN AH	09/22/21	0.70	DRAFT MEMO (0.7).
CHAN AH	09/23/21	3.60	DRAFT MEMO (3.6).
CHAN AH	09/23/21	1.30	PROPOSE REVISIONS TO SLIDE-DECK (1.3).
CHAN AH	09/28/21	2.40	REVISE AGREEMENT (2.4).
CHAN AH	09/28/21	0.40	REVISE MEMO (0.4).
CHAN AH	09/30/21	0.20	REVISE MEMO RE: REGULATORY ISSUE (0.2).

**28.50**

DICKS-MIREAUX L 09/29/21 2.30 RESEARCH RE: APPLICABLE REGULATIONS (2.3).

DICKS-MIREAUX L 09/30/21 2.70 CONTINUE RESEARCH RE: APPLICABLE REGULATIONS (2.7).

**5.00**

ICKES KR 09/02/21 1.20 REVIEW AND ANALYZE CERTAIN MATERIAL RE: TRANSACTIONAL ISSUE (1.2).

**1.20**

**Total Associate** **34.70**

**MATTER TOTAL** **74.90**

Purdue Pharma L.P.  
DOJ

**Bill Date:** 11/03/21  
**Bill Number:** 1871286

NAME	DATE	HOURS	DESCRIPTION
BRAGG JL	09/01/21	6.80	LISTEN TO BANKRUPTCY HEARING (6.8).
BRAGG JL	09/02/21	1.00	BOARD MEETING (1.0).
BRAGG JL	09/09/21	0.60	CONFER WITH CO-COUNSEL RE: DOJ ISSUES (0.6).
BRAGG JL	09/10/21	1.00	WEEKLY DOJ CALL (1.0).
BRAGG JL	09/12/21	0.50	CONFER WITH CLIENT RE: DOJ ISSUES (0.5).
BRAGG JL	09/14/21	1.30	CALL WITH CLIENT AND CO-COUNSEL RE: DOJ ISSUES (0.5); ATTEND WEEKLY PRINCIPAL CALL (0.6) CONFER RE: SAME (0.2).
BRAGG JL	09/15/21	2.40	PREPARE FOR MEETING WITH CLIENT (0.8); MEETING WITH CLIENT (1.6).
BRAGG JL	09/17/21	1.70	CALL WITH CLIENT RE: DOJ ISSUES (1.3); CONFER WITH CO-COUNSEL RE: DOJ ISSUE (0.4).
BRAGG JL	09/18/21	0.50	CONFER WITH CO-COUNSEL RE: DOJ ISSUES (0.5).
BRAGG JL	09/21/21	0.50	CONFER WITH CO-COUNSEL RE: DOJ ISSUES (0.5).
BRAGG JL	09/22/21	1.00	CONFER WITH CO-COUNSEL RE: DOJ ISSUES (1.0).
BRAGG JL	09/23/21	1.40	CONFER WITH CO-COUNSEL RE: DOJ ISSUES (0.9); CONFER WITH CLIENT RE: DOJ ISSUES (0.5).
BRAGG JL	09/24/21	2.10	CONFER WITH CO-COUNSEL RE: DOJ ISSUES (0.7); REVIEW AND ANALYSIS OF DOJ ISSUES (0.9); CONFER WITH CO-COUNSEL RE: DOJ ISSUES (0.5).
BRAGG JL	09/27/21	1.00	CONFER WITH CO-COUNSEL RE: DOJ ISSUES (1.0).
BRAGG JL	09/28/21	3.70	ATTEND WEEKLY PRINCIPAL CALL (0.7); PREPARE FOR MEETING (1.3); ATTEND MEETING (1.7).
		<b>25.50</b>	
FITZGERALD P	09/01/21	2.80	ATTENTION TO ORAL RULING (2.8).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FITZGERALD P	09/02/21	1.70	ANALYZE AND REVIEW ISSUES RE: DOJ PROCEEDINGS (0.5); PARTICIPATE IN BOARD CALL (1.2).
FITZGERALD P	09/08/21	0.20	ANALYZE AND REVIEW DOJ ISSUES IN BANKRUPTCY (0.2).
FITZGERALD P	09/09/21	0.40	CALL WITH DOJ, CO-COUNSEL AND M. FLORENCE REGARDING DOJ REQUEST (0.3); DOJ UPDATE WITH CO-COUNSEL (0.1).
FITZGERALD P	09/10/21	0.50	CONFER WITH OUTSIDE COUNSEL AND DOJ REGARDING DOJ ISSUES INVOLVING BANKRUPTCY (0.5).
FITZGERALD P	09/14/21	1.90	CALL WITH CLIENT , CO-COUNSEL AND M. FLORENCE REGARDING DOJ REQUEST (0.4); FOLLOW-UP INTERVIEW REGARDING DOJ REQUEST (0.3); CONFER WITH M. FLORENCE RE: DOJ ISSUE (0.1); CORRESPOND WITH CO-COUNSEL, CLIENT AND SKADDEN TEAM RE: DOJ ISSUE (0.5); ATTEND WEEKLY PRINCIPALS CALL (0.6).
FITZGERALD P	09/15/21	0.20	REVIEW AND ANALYZE BANKRUPTCY ISSUES REGARDING DOJ (0.2).
FITZGERALD P	09/16/21	0.20	REVIEW AND ANALYZE DOJ ISSUES IN BANKRUPTCY (0.2).
FITZGERALD P	09/17/21	0.50	UPDATE CALL WITH DOJ (0.5).
FITZGERALD P	09/18/21	0.80	CALL WITH CO-COUNSEL REGARDING DOJ ISSUE (0.1); REVIEW MATERIALS (0.2); STRATEGY CALL WITH CO-COUNSEL AND SKADDEN TEAM (0.5).
FITZGERALD P	09/19/21	0.50	REVIEW FILING (0.5).
FITZGERALD P	09/20/21	0.90	ATTENTION TO ISSUE REGARDING DOJ REQUEST (0.6); CORRESPONDENCE REGARDING DOJ ISSUE (0.3).
FITZGERALD P	09/21/21	2.30	CONFER WITH SKADDEN TEAM REGARDING DOJ ISSUE(0.6); FOLLOW UP ON DOJ ISSUES (1.7).
FITZGERALD P	09/22/21	5.10	ANALYZE DOJ ISSUES (4.2); CALL WITH CO-COUNSEL AND M. FLORENCE RE: DOJ ISSUES (0.9).

## Skadden, Arps, Slate, Meagher &amp; Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FITZGERALD P	09/23/21	2.30	CALL WITH CLIENT, CO-COUNSEL, OUTSIDE COUNSEL AND SKADDEN TEAM RE: DOJ ISSUES(1.0); CALL WITH OUTSIDE COUNSEL AND CO-COUNSEL AND M. FLORENCE REGARDING DOJ ISSUE (0.4); REVIEW DRAFT ANALYSIS (0.4); CALL WITH DOJ TEAM, CO-COUNSEL AND M. FLORENCE RE: DOCUMENT REQUESTS (0.3); COMMUNICATE WITH OUTSIDE COUNSEL REGARDING DOJ ISSUE (0.2).
FITZGERALD P	09/24/21	1.80	CALL WITH W. RIDGEWAY, AND CLIENT RE: DOJ STRATEGY(0.4); CALL WITH OUTSIDE COUNSEL RE: DOJ ISSUES (0.5); CALL WITH CO-COUNSEL AND SKADDEN REGARDING DOJ STRATEGY (0.9).
FITZGERALD P	09/27/21	1.80	UPDATE CALL WITH CO-COUNSEL (0.3); REVIEW CASE UPDATE AND CASE LAW (0.4); CONFER WITH CO-COUNSEL (0.3); CALL WITH CO-COUNSEL AND SKADDEN TEAM RE: DOJ STRATEGY (0.8).
FITZGERALD P	09/28/21	1.50	REVIEW AND ANALYZE DOJ ISSUE(0.3); CONFER WITH OUTSIDE COUNSEL (0.2); UPDATE WITH CO-COUNSEL (0.3); ATTEND WEEKLY PRINCIPALS CALL (0.7).
FITZGERALD P	09/29/21	1.40	REVIEW DOJ ISSUE (0.3); UPDATE CALL WITH CO-COUNSEL(0.4); FOLLOW-UP ON DOJ ISSUE (0.3); UPDATE CALL WITH CO-COUNSEL (0.4).
FITZGERALD P	09/30/21	3.90	CALL WITH CO-COUNSEL (0.3); CALL WITH CO-COUNSEL AND CLIENT (0.6); CONFER WITH M. FLORENCE RE: DOJ ISSUES (0.4); REVIEW MATERIALS REGARDING DOJ ISSUE (0.6); UPDATE WITH M. FLORENCE (0.2); ATTEND HEARING (1.0); CALL WITH DOJ REGARDING DOCUMENT REQUEST (0.5); UPDATE CALL WITH CO-COUNSEL (0.3).
		<b>30.70</b>	
FLORENCE MP	09/08/21	0.20	CORRESPOND WITH CLIENT AND VENDOR RE: DATABASE (0.2).
FLORENCE MP	09/09/21	0.30	CALL WITH DOJ, P. FITZGERALD AND CO-COUNSEL RE: DOJ REQUEST (0.3).
FLORENCE MP	09/12/21	0.10	REVIEW PROPOSED RESPONSE RE: DOJ REQUEST (0.1).
FLORENCE MP	09/13/21	0.10	CORRESPOND WITH CO-COUNSEL RE: DOJ REQUEST (0.1).

## Skadden, Arps, Slate, Meagher &amp; Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

FLORENCE MP	09/14/21	1.50	CALL WITH CLIENT, CO-COUNSEL, AND P. FITZGERALD RE: DOJ REQUEST (0.4); CONFER WITH CLIENT RE: DOJ STRATEGY (0.6); PARTICIPATE IN WEEKLY PRINCIPALS STRATEGY CALL (0.5).
FLORENCE MP	09/17/21	0.40	CONFER WITH DOJ AND CO-COUNSEL RE: DOCUMENT REQUESTS (0.4).
FLORENCE MP	09/18/21	0.70	CORRESPOND WITH CO-COUNSEL RE: DOJ MATTER STATUS (0.2); STRATEGY CALL WITH CO-COUNSEL AND SKADDEN TEAM (0.5).
FLORENCE MP	09/19/21	0.50	REVIEW AND EDIT DRAFT AGREEMENT (0.5).
FLORENCE MP	09/20/21	1.60	REVISE DRAFT AGREEMENT (0.8); CONFER WITH DOJ AND CO-COUNSEL RE: DOCUMENT REQUESTS (0.8).
FLORENCE MP	09/21/21	1.40	CORRESPOND WITH SKADDEN TEAM AND CO-COUNSEL RE: DOJ ISSUES (1.2); CORRESPOND WITH OUTSIDE COUNSEL (0.2).
FLORENCE MP	09/22/21	3.50	REVIEW MATERIALS RE: DOJ ISSUES (0.9); PARTICIPATE IN CALL WITH CO-COUNSEL AND P. FITZGERALD RE: SAME (0.6); CONFER WITH SKADDEN TEAM AND CO-COUNSEL RE: DOJ ISSUES (1.0); CORRESPOND WITH CO-COUNSEL RE: SAME (1.0).
FLORENCE MP	09/23/21	1.90	CALL WITH CLIENT, CO-COUNSEL, OUTSIDE COUNSEL AND SKADDEN TEAM RE: DOJ ISSUES (1.0); CALL WITH OUTSIDE COUNSEL, CO-COUNSEL AND P. FITZGERALD RE: DOJ ISSUES (0.5); PARTICIPATE IN CALL WITH P. FITZGERALD, CO-COUNSEL AND DOJ RE: DOCUMENT REQUESTS (0.4).
FLORENCE MP	09/24/21	1.10	CALL WITH CO-COUNSEL AND SKADDEN TEAM RE: DOJ STRATEGY (1.1).
FLORENCE MP	09/27/21	1.80	CORRESPOND WITH CO-COUNSEL AND SKADDEN TEAM RE: DOJ REQUESTS (0.6); CONFER WITH SKADDEN TEAM RE: SAME (0.3); CONFER WITH CO-COUNSEL RE: SAME (0.4); CONFER WITH CO-COUNSEL AND SKADDEN TEAM RE: DOJ STRATEGY (0.5).
FLORENCE MP	09/28/21	0.90	CORRESPOND WITH DOJ AND SKADDEN TEAM RE: REQUESTS (0.2); ATTEND WEEKLY PRINCIPALS CALL (0.6); CONFER WITH P. FITZGERALD RE: DOJ REQUEST (0.1).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**

ATTORNEY WORK PRODUCT

**PRIVILEGED AND CONFIDENTIAL**

FLORENCE MP	09/30/21	4.50	CONFER WITH CO-COUNSEL AND SKADDEN TEAM RE: DOJ REQUESTS (1.4); CORRESPOND WITH CO-COUNSEL RE: SAME (0.5); ATTEND BANKRUPTCY HEARING (1.1); PARTICIPATE IN CALL WITH DOJ RE: DOCUMENT REQUESTS (0.5); DRAFT EMAIL TO DOJ RE: SAME (0.5); CORRESPOND WITH SKADDEN TEAM RE: DOJ ISSUES (0.5).
		<b>20.50</b>	
RIDGWAY W	09/02/21	0.30	FOLLOW UP ON DOJ ISSUES (0.3).
RIDGWAY W	09/09/21	0.20	CONFER WITH SKADDEN TEAM RE: DOJ ISSUES (0.2).
RIDGWAY W	09/10/21	0.60	CONFER WITH SKADDEN TEAM RE: PRESENTATION FOR DOJ MATTERS (0.3); REVIEW DECK RE: DOJ MATTERS (0.3).
RIDGWAY W	09/14/21	0.90	PARTICIPATE IN WEEKLY PRINCIPALS CALL (0.6); CONFER WITH SKADDEN TEAM RE: DOJ ISSUES (0.3).
RIDGWAY W	09/15/21	2.00	PREPARE FOR PRESENTATION RE: DOJ ISSUES; AND PARTICIPATE IN SAME (2.0).
RIDGWAY W	09/17/21	1.40	CONFER WITH CLIENT, OUTSIDE COUNSEL, AND SKADDEN TEAM RE: BANKRUPTCY AND DOJ ISSUES (1.2); CONFER WITH SKADDEN TEAM RE: DOJ STRATEGY (0.2).
RIDGWAY W	09/18/21	0.40	CONFER WITH CLIENT AND CO-COUNSEL RE: DOJ MATTERS AND STRATEGY (0.4).
RIDGWAY W	09/20/21	0.40	CONFER WITH SKADDEN TEAM RE: POTENTIAL ENGAGEMENT AND DOJ MATTERS (0.4).
RIDGWAY W	09/21/21	1.90	CONFER WITH SKADDEN TEAM AND CO-COUNSEL RE: DOJ PROCEEDINGS (0.8); ANALYZE DOJ RELATED MATERIALS (1.1).
RIDGWAY W	09/22/21	1.70	CONFER WITH SKADDEN TEAM AND CO-COUNSEL RE: SENTENCING ISSUE (1.0); ANALYZE MATERIALS RE: DOJ ISSUES (0.7).
RIDGWAY W	09/23/21	1.60	CONFER WITH SKADDEN TEAM AND CO-COUNSEL RE: SENTENCING ISSUE (1.0); ANALYZE MATERIALS RE: DOJ ISSUES (0.6).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**

ATTORNEY WORK PRODUCT

**PRIVILEGED AND CONFIDENTIAL**

RIDGWAY W	09/24/21	1.40	CALL WITH P. FITZGERALD AND CLIENT RE: DOJ STRATEGY (0.4); CALL WITH SKADDEN TEAM AND CO-COUNSEL RE: DOJ STRATEGY (1.0).
RIDGWAY W	09/27/21	1.50	REVIEW DOJ REQUEST (0.3); CONFER WITH SKADDEN TEAM RE: DOJ REQUEST (0.4); CALL WITH CO-COUNSEL AND SKADDEN TEAM RE: DOJ STRATEGY (0.8).
RIDGWAY W	09/28/21	0.60	REVIEW MATERIALS RE: DOJ STRATEGY (0.6).
RIDGWAY W	09/29/21	0.50	ANALYZE UPDATE RE: DOJ MATTERS AND STRATEGY (0.5).
RIDGWAY W	09/30/21	1.00	CONFER WITH DOJ RE: PRODUCTIONS (0.7); CONFER WITH SKADDEN TEAM AND CLIENT RE: DOJ ISSUES (0.3).
		<b>16.40</b>	
<b>Total Partner</b>		<b>93.10</b>	
AMAECHI PI	09/29/21	3.30	RESEARCH AND SUMMARIZE CASE LAW RE: DOJ ISSUES (3.3).
		<b>3.30</b>	
BEJAN WA	09/27/21	0.20	CALL WITH SKADDEN TEAM RE: DOJ ISSUES (0.2).
BEJAN WA	09/27/21	0.20	REVIEW AND ANALYZE DOCUMENTS RE: DOJ ISSUES (0.2).
		<b>0.40</b>	
BERRY EL	09/23/21	0.10	CONFER WITH SKADDEN TEAM RE: REGULATORY ISSUES (0.1).
BERRY EL	09/27/21	1.80	CONDUCT RESEARCH RE: DOJ ISSUES (1.8).
BERRY EL	09/28/21	0.60	CONDUCT RESEARCH RE: DOJ ISSUES (0.6).
BERRY EL	09/29/21	2.50	CONTINUE RESEARCH RE: DOJ ISSUES (2.5).
BERRY EL	09/30/21	1.20	CONDUCT RESEARCH RE: DOJ ISSUES (1.2).
		<b>6.20</b>	
CHAN AH	09/09/21	2.20	REVISE MATERIALS RE: DOJ ISSUES (2.2).
		<b>2.20</b>	

Skadden, Arps, Slate, Meagher &amp; Flom LLP and affiliates

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

HELLMAN E	09/03/21	0.50	REVIEW MATERIAL FOR PRIVILEGE RE: OUTSIDE PRODUCTION (0.4); CORRESPOND RE: SAME (0.1).
HELLMAN E	09/30/21	2.50	REVIEW AND ANALYZE MATERIALS IN RESPONSE TO DOJ REQUEST (2.5).
		<b>3.00</b>	
HOUSTON CD	09/27/21	0.30	ATTEND CALL WITH TEAM TO DISCUSS DOJ REQUESTS (0.3).
		<b>0.30</b>	
<b>Total Associate</b>		<b>15.40</b>	
<b>MATTER TOTAL</b>		<b><u>108.50</u></b>	

Purdue Pharma L.P.  
General Advice

Bill Date: 11/03/21  
Bill Number: 1871287

NAME	DATE	HOURS	DESCRIPTION
BRAGG JL	09/09/21	0.40	CONFER WITH CLIENT RE: PROMOTIONAL ISSUES (0.4).
BRAGG JL	09/10/21	1.00	CONFER WITH CLIENT RE: PROGRAMMATIC MATTERS (1.0).
BRAGG JL	09/15/21	0.50	CONFER WITH CLIENT RE: PUBLICATION (0.5).
BRAGG JL	09/27/21	1.00	CONFER WITH CLIENT RE: COMPLIANCE MATTERS (1.0).
		<b>2.90</b>	
FLORENCE MP	09/09/21	0.80	CONFER WITH M. FELTZ AND R. SILBERT RE: LESSONS LEARNED PRESENTATION (0.8).
FLORENCE MP	09/10/21	1.50	CONFER WITH J. BRAGG RE: PRESENTATION TO CLIENT (0.2); CONFER WITH J. BRAGG AND W. RIDGWAY RE: SAME (0.2); REVISE SLIDE DECK FOR SAME (0.2); CONFER WITH M. FELTZ AND J. BRAGG RE: ADVICE MATTERS (0.9).
FLORENCE MP	09/15/21	1.50	PARTICIPATE IN MEETING WITH CLIENT RE: LESSONS LEARNED (1.5).
FLORENCE MP	09/27/21	1.00	CONFER WITH CLIENT AND J. BRAGG RE: REGULATORY ADVICE MATTERS (1.0).
		<b>4.80</b>	
<b>Total Partner</b>		<b>7.70</b>	
<b>MATTER TOTAL</b>		<b><u>7.70</u></b>	

Purdue Pharma L.P.  
General Compliance

**Bill Date:** 11/03/21  
**Bill Number:** 1871288

NAME	DATE	HOURS	DESCRIPTION
BRAGG JL	09/10/21	2.80	CONFER WITH CO-COUNSEL RE: COMPLIANCE ISSUES (0.7); CONFER WITH CO-COUNSEL RE: COMPLIANCE ISSUE (0.7); REVIEW CUSTOMER SERVICE DOCUMENTS (1.4).
BRAGG JL	09/13/21	1.70	CALL WITH CLIENT RE: COMPLIANCE REVIEW (0.5); REVIEW AND ANALYSIS OF MEETINGS RE: COMPLIANCE (0.9); CONFER WITH CO-COUNSEL RE: COMPLIANCE REVIEW (0.3).
BRAGG JL	09/15/21	0.40	CONFER WITH CO-COUNSEL RE: COMPLIANCE (0.4).
BRAGG JL	09/16/21	1.50	CONFER WITH CO-COUNSEL RE: COMPLIANCE REVIEW( 0.7); REVIEW AND ANALYSIS OF COMPLIANCE PROPOSAL (0.8).
BRAGG JL	09/17/21	0.40	CONFER WITH CO-COUNSEL RE: COMPLIANCE REVIEW (0.4).
BRAGG JL	09/20/21	0.60	CONFER WITH CO-COUNSEL RE: COMPLIANCE REVIEW (0.6).
BRAGG JL	09/21/21	1.00	CONFER WITH CO-COUNSEL RE: COMPLIANCE REVIEW (0.5); CONFER WITH CLIENT RE: COMPLIANCE REVIEW (0.5).
BRAGG JL	09/22/21	1.30	REVIEW COMPLIANCE MATERIALS (0.4); CALL WITH COMPLIANCE (0.5); CONFER WITH CLIENT RE: COMPLIANCE RELATED ISSUES (0.4).
		<b>9.70</b>	
<b>Total Partner</b>		<b>9.70</b>	
DUNN AM	09/16/21	3.10	REVIEW ISSUES RELATED TO COMPLIANCE REVIEW (3.1).
DUNN AM	09/16/21	0.30	PARTICIPATE ON CALL WITH CO-COUNSEL RE: COMPLIANCE REVIEW (0.3).
DUNN AM	09/20/21	3.20	ANALYZE AND PROVIDE COMMENTS ON DRAFT VENDOR AGREEMENT (3.2).
DUNN AM	09/20/21	0.50	PARTICIPATE ON CALL RE: COMPLIANCE REVIEW (0.5).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**

ATTORNEY WORK PRODUCT

**PRIVILEGED AND CONFIDENTIAL**

DUNN AM	09/20/21	0.60	DRAFT TALKING POINTS (0.6).
DUNN AM	09/22/21	0.60	REVIEW AND RESPOND TO CORRESPONDENCE RE: COMPLIANCE REVIEW (0.6).
DUNN AM	09/22/21	0.80	PREPARE FOR AND PARTICIPATE ON CALL RE: COMPLIANCE REVIEW (0.8).
DUNN AM	09/27/21	1.20	REVIEW DOCUMENT REQUESTS (1.2).
DUNN AM	09/27/21	0.50	PARTICIPATE ON CALL RE: COMPLIANCE REVIEW (0.5).
DUNN AM	09/29/21	1.30	REVIEW RESEARCH MEMORANDUM (1.3).
DUNN AM	09/30/21	0.40	PARTICIPATE ON CALL WITH CO-COUNSEL (0.4).
DUNN AM	09/30/21	0.70	RESPOND TO CORRESPONDENCE RE: COMPLIANCE REVIEW (0.7).
		<b>13.20</b>	
<b>Total Counsel</b>		<b>13.20</b>	
BERRY EL	09/27/21	0.50	CALL WITH SKADDEN TEAM RE: COMPLIANCE REVIEW (0.5).
BERRY EL	09/28/21	0.20	CALL WITH A. DUNN RE: COMPLIANCE REVIEW (0.2).
BERRY EL	09/29/21	2.10	REVIEW AND ASSESS MATERIALS RE: COMPLIANCE (2.1).
BERRY EL	09/30/21	1.00	CALL WITH A. DUNN RE: WORK PRODUCT (0.1); REVIEW DOCUMENTS AND EMAILS RE: SAME RE: COMPLIANCE REVIEW (0.7); CALL WITH A. DUNN, J. ADAMS, AND OTHERS RE: COMPLIANCE REVIEW (0.2).
		<b>3.80</b>	
<b>Total Associate</b>		<b>3.80</b>	
HOHMANN MJ	09/29/21	1.30	COMM. WITH ATTORNEY RE: PREPARING LOG OF SELECT PURDUE POLICIES AND PROCEDURES; REVIEW/EXTRACT MATERIALS PROVIDED BY ATTORNEY AND POPULATE LOG WITH REQUESTED INFO; SAVE/SEND LOG TO ATTORNEY WITH NOTES (1.3).
		<b>1.30</b>	
<b>Total Legal Assistant</b>		<b>1.30</b>	
<b>MATTER TOTAL</b>		<b><u>28.00</u></b>	

Purdue Pharma L.P.  
Healthcare Law Compliance

**Bill Date:** 11/03/21  
**Bill Number:** 1871289

NAME	DATE	HOURS	DESCRIPTION
DUNN AM	09/01/21	3.50	REVISE HEALTHCARE COMPLIANCE POLICY (3.5).
DUNN AM	09/02/21	0.30	PARTICIPATE ON CALL WITH CO-COUNSEL RE: COMPLIANCE POLICY REVIEW (0.3).
DUNN AM	09/20/21	1.60	REVISE DRAFT COMPLIANCE POLICY (1.6).
DUNN AM	09/23/21	4.40	REVISE DRAFT COMPLIANCE POLICY SECTIONS (4.4).
DUNN AM	09/23/21	0.60	PARTICIPATE ON CALL WITH CLIENT RE: COMPLIANCE POLICY (0.6).
		<b>10.40</b>	
<b>Total Counsel</b>		<b>10.40</b>	
BERRY EL	09/28/21	1.00	REVIEW AND UPDATE COMPLIANCE POLICIES (1.0).
BERRY EL	09/29/21	2.30	CONTINUE REVIEW AND UPDATE COMPLIANCE POLICIES (2.3).
BERRY EL	09/30/21	1.40	REVIEW AND UPDATE COMPLIANCE POLICIES (1.4).
		<b>4.70</b>	
CHAN AH	09/01/21	1.30	DRAFT POLICY UPDATE (1.3).
CHAN AH	09/02/21	0.50	CONFER ON NEXT STEPS RE: POLICY UPDATE (0.5).
CHAN AH	09/07/21	0.10	REVISE COMPLIANCE POLICY (0.1).
CHAN AH	09/08/21	5.20	DRAFT COMPLIANCE POLICY UPDATE (5.2).
CHAN AH	09/20/21	2.90	DRAFT COMPLIANCE POLICY UPDATE (2.9).
CHAN AH	09/22/21	2.10	DRAFT COMPLIANCE POLICY UPDATE (2.1).
CHAN AH	09/23/21	0.20	DRAFT COMPLIANCE POLICY UPDATE (0.2).
CHAN AH	09/23/21	0.40	CONFER WITH CLIENT ON NEXT STEPS FOR COMPLIANCE POLICY UPDATE (0.4).

CHAN AH	09/23/21	0.50	CONDUCT FOLLOW-UP ON COMPLIANCE POLICY UPDATE (0.5).
CHAN AH	09/23/21	1.50	DRAFT COMPLIANCE POLICY UPDATE (1.5).
CHAN AH	09/23/21	0.10	CONFER ON NEXT STEPS (0.1).
CHAN AH	09/24/21	1.00	DRAFT COMPLIANCE POLICY UPDATE (1.0).
CHAN AH	09/27/21	3.50	DRAFT COMPLIANCE POLICY UPDATE (3.5).
CHAN AH	09/27/21	0.50	CONFER ON NEXT STEPS FOR POLICY UPDATE (0.5).
CHAN AH	09/28/21	2.20	DRAFT COMPLIANCE POLICY UPDATE (2.2).
CHAN AH	09/29/21	1.10	DRAFT COMPLIANCE POLICY UPDATE (1.1).
CHAN AH	09/30/21	0.20	DRAFT COMPLIANCE POLICY UPDATE (0.2).
		<b>23.30</b>	
DICKS-MIREAUX L	09/27/21	0.50	CONFER ON NEXT STEPS FOR POLICY UPDATE (0.5).
		<b>0.50</b>	
OPPENHEIMER L	09/27/21	0.20	REVIEW COMPLIANCE POLICY (0.2).
OPPENHEIMER L	09/27/21	0.50	CONFER ON NEXT STEPS FOR POLICY UPDATE (0.5).
		<b>0.70</b>	
<b>Total Associate</b>		<b>29.20</b>	
<b>MATTER TOTAL</b>		<b><u>39.60</u></b>	

Purdue Pharma L.P.  
Litigation Discovery Issues

Bill Date: 11/03/21  
Bill Number: 1871290

NAME	DATE	HOURS	DESCRIPTION
MCCONAGHA W	09/01/21	0.50	CALL WITH CLIENT RE: REGULATORY UPDATE (0.5).
MCCONAGHA W	09/01/21	0.50	REVIEW AND REVISE REGULATORY UPDATE (0.5).
MCCONAGHA W	09/10/21	1.00	FINALIZE UPDATE LETTER; DRAFT COVER EMAIL TO FDA; AND SUBMIT PACKAGE TO FDA (1.0).
		2.00	
<b>Total Partner</b>		<b>2.00</b>	
<b>MATTER TOTAL</b>		<b><u>2.00</u></b>	

Purdue Pharma L.P.  
Project Catalyst

Bill Date: 11/03/21  
Bill Number: 1871291

NAME	DATE	HOURS	DESCRIPTION
GIBSON ML	09/29/21	1.50	REVIEWED MATERIALS FOR CLIENT QUESTION (0.9); CALLS WITH CLIENT (0.2); CALLS AND CORRESPONDENCE WITH INTERNAL TEAM ON ANALYSIS (0.4).
		1.50	
<b>Total Partner</b>		<b>1.50</b>	
ICKES KR	09/28/21	1.10	REVIEW MATERIALS FOR CLIENT QUESTION (1.1).
ICKES KR	09/29/21	0.50	PREPARE FOR CALL WITH CLIENT (0.3); CALL WITH CLIENT (0.2).
		1.60	
YUH C	09/29/21	1.50	REVIEW MATERIAL RE: CLIENT QUESTION (1.5).
		1.50	
<b>Total Associate</b>		<b>3.10</b>	
<b>MATTER TOTAL</b>		<b><u>4.60</u></b>	

Purdue Pharma L.P.  
Retention/Fee Matter

**Bill Date:** 11/03/21  
**Bill Number:** 1871292

NAME	DATE	HOURS	DESCRIPTION
BRAGG JL	09/06/21	1.20	REVIEW AND ANALYZE RETENTION MATERIALS (1.2).
BRAGG JL	09/10/21	1.10	CONFER WITH CO-COUNSEL RE: RETENTION FEE ISSUES (0.6); CONFER WITH CO-COUNSEL RE: RETENTION FEE ISSUES (0.5).
		<b>2.30</b>	
CLARK AW	09/08/21	0.40	WORK ON ISSUES RE: SUPPLEMENTAL DISCLOSURE MATTERS (0.3); REVIEW RELATED CORRESPONDENCE WITH SKADDEN TEAM (0.1).
CLARK AW	09/16/21	1.60	WORK ON ISSUES RE: SUPPLEMENTAL DISCLOSURE RE: NEW LATERAL PERSONNEL (0.4); AND ENDO ENGAGEMENT (0.4); REVIEW RELATED CORRESPONDENCE WITH SKADDEN TEAM (0.8).
CLARK AW	09/17/21	0.80	WORK ON SUPPLEMENTAL DISCLOSURE ISSUES RE: ENDO ENGAGEMENT (0.4); REVIEW CORRESPONDENCE WITH SKADDEN TEAM (0.4).
CLARK AW	09/21/21	2.10	FINALIZE SUPPLEMENTAL DISCLOSURE DECLARATION RE: NEW ENDO ENGAGEMENT (1.1); REVIEW RELATED CORRESPONDENCE WITH SKADDEN TEAM (0.7); TELECONFERENCE WITH L. SPIEGEL, J. TURNER, J. MADDEN (0.3).
CLARK AW	09/24/21	0.40	REVIEW JUNE FEE STATEMENT (0.3) AND RELATED CORRESPONDENCE WITH SKADDEN TEAM (0.1).
		<b>5.30</b>	
FLORENCE MP	09/08/21	0.40	CORRESPOND WITH SKADDEN TEAM AND CLIENT RE: MATTER BUDGETS (0.4).
FLORENCE MP	09/10/21	0.70	CONFER WITH CO-COUNSEL RE: BILLING PROCESS (0.7).
FLORENCE MP	09/18/21	0.20	CORRESPOND WITH CLIENT RE: BUDGETS (0.2).
		<b>1.30</b>	
<b>Total Partner</b>		<b>8.90</b>	

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**

ATTORNEY WORK PRODUCT

**PRIVILEGED AND CONFIDENTIAL**

BAILEY MS	09/10/21	0.50	CALL WITH SKADDEN TEAM RE: FEE APPLICATION QUESTIONS AND PLANNING (0.5).
BAILEY MS	09/24/21	0.70	CALL WITH SKADDEN TEAM RE: FEE APPLICATION OVERVIEW AND PROCEDURES (0.7).
<b>1.20</b>			
<b>Total Counsel</b>			<b>1.20</b>
DEAN B	09/06/21	1.20	ANALYZE FEE RETENTION MATERIALS (1.0); CORRESPOND WITH SKADDEN TEAM RE: SAME (0.2).
DEAN B	09/07/21	0.70	REVISE FEE RETENTION MATERIALS (0.5); CORRESPOND WITH SKADDEN TEAM RE: SAME (0.2).
DEAN B	09/08/21	0.50	REVISE FEE APPLICATION MATERIALS (0.3); CORRESPOND WITH SKADDEN TEAM RE: SAME (0.2).
DEAN B	09/10/21	0.40	DRAFT JUNE MONTHLY FEE STATEMENT (0.4).
DEAN B	09/20/21	0.20	CALL WITH L. KATZ RE: RETENTION FEE STATEMENT MATERIALS (0.2).
DEAN B	09/21/21	1.40	ANALYZE FEE RETENTION MATERIALS (1.4).
DEAN B	09/22/21	1.00	ANALYZE RETENTION FEE MATERIALS (1.0).
DEAN B	09/24/21	2.10	CALL WITH SKADDEN TEAM RE: RETENTION TRANSITION (0.8); IMPLEMENT FINAL REVISIONS TO JUNE INTERIM FEE STATEMENT (0.2); CORRESPOND WITH SKADDEN TEAM RE: FILING OF SAME (0.1); CALL WITH E. HELLMAN RE: RETENTION TRANSITION PROCESS (1.0).
DEAN B	09/27/21	1.00	ATTENTION TO INTERIM FEE STATEMENT (1.0).
DEAN B	09/28/21	0.70	IMPLEMENT REVISIONS TO FEE STATEMENT MATERIALS (0.6); CONFER WITH E. HELLMAN RE: SAME (0.1).
<b>9.20</b>			
HELLMAN E	09/24/21	2.20	CONFER WITH SKADDEN TEAM RE: BILLING TRANSITION PROCESS (0.8); CALL WITH B. DEAN RE: BILLING TRANSITION PROCESS (1.0); REVIEW FEE STATEMENT MATERIALS (0.4).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates****ATTORNEY WORK PRODUCT****PRIVILEGED AND CONFIDENTIAL**

HELLMAN E	09/27/21	5.80	REVIEW AND EDIT FEE STATEMENT MATERIALS (3.9); REVISE RETENTION GUIDANCE (1.4); CONFER WITH B. DEAN REGARDING FEE STATEMENT REVISIONS (0.5).
HELLMAN E	09/28/21	5.00	REVIEW AND REVISE FEE STATEMENT MATERIALS (5.0).
HELLMAN E	09/29/21	5.90	REVIEW AND REVISE FEE STATEMENTS (5.9).
HELLMAN E	09/30/21	4.40	REVIEW AND REVISE FEE STATEMENTS (4.4).
<b>23.30</b>			
MADDEN J	09/07/21	0.30	CORRESPONDENCE REGARDING FEE APPLICATION (0.2); REVIEW CORRESPONDENCE RE: DISCLOSURES (0.1).
MADDEN J	09/09/21	1.20	REVIEW/REVISE FEE MATERIALS (0.9); CORRESPONDENCE RE: FEE MATTERS (0.3).
MADDEN J	09/10/21	0.90	CORRESPONDENCE WITH TEAM REGARDING JUNE MONTHLY STATEMENT (0.6); CORRESPONDENCE REGARDING FEE APP BUDGET (0.3).
MADDEN J	09/13/21	0.40	ANALYSIS RE: DISCLOSURES (0.4).
MADDEN J	09/14/21	1.90	DISCUSS DISCLOSURE MATTER (0.2); DRAFT SUPPLEMENTAL DISCLOSURE (0.9); FOLLOW UP CORRESPONDENCE AND REVISIONS RE: SAME (0.5); COORDINATE FILING RE: SAME (0.3).
MADDEN J	09/15/21	2.70	CALL WITH TEAM (0.4) AND PREPARE MATERIALS RE: DECLARATION/DISCLOSURES (1.2); COORDINATE RE: SAME (0.4); REVIEW COMMENTS TO SAME /REVISE DOC. (0.7).
MADDEN J	09/16/21	0.90	UPDATE DECLARATION (0.6); CORRESPONDENCE RE: SAME (0.3).
MADDEN J	09/17/21	0.80	CORRESPONDENCE RE: JUNE MONTHLY FEE STATEMENT (0.2); CORRESPONDENCE RE: PURDUE DISCLOSURE (0.6).
MADDEN J	09/21/21	1.00	FINALIZE DISCLOSURE AND COORDINATE FILING OF SAME (0.6); CORRESPONDENCE RE: SAME (0.4).
MADDEN J	09/24/21	0.70	REVIEW MONTHLY FEE MATERIALS (0.4) AND CORRESPONDENCE WITH TEAM RE SAME (0.3).

MADDEN J	09/27/21	0.60	RESEARCH RE: DISCLOSURES (0.5); CORRESPONDENCE RE: MONTHLY STATEMENTS (0.1).
		<b>11.40</b>	
O'HARE WS	09/30/21	0.90	PREPARE FEE APPLICATION MATERIALS (0.9).
		<b>0.90</b>	
<b>Total Associate</b>		<b>44.80</b>	
CAMPANA MD	09/21/21	0.90	ASSIST WITH FILING OF THE FIFTH SUPPLEMENTAL DECLARATION OF ANTHONY CLARK IN THE U.S. BANKRUPTCY COURT, SOUTHERN DISTRICT OF NEW YORK, CASE NO. 19-23649 (0.9).
CAMPANA MD	09/27/21	0.60	ASSIST WITH FILING OF THE JUNE MONTHLY FEE STATEMENT WITH THE U.S. BANKRUPTCY COURT, SOUTHERN DISTRICT NEW YORK, CASE NO. 19-23649 (0.6).
		<b>1.50</b>	
<b>Total Legal Assistant</b>		<b>1.50</b>	
<b>MATTER TOTAL</b>		<b><u>56.40</u></b>	

Purdue Pharma L.P.  
Rhodes Companies

Bill Date: 11/03/21  
Bill Number: 1871293

NAME	DATE	HOURS	DESCRIPTION
FLORENCE MP	09/12/21	0.30	CORRESPOND WITH CLIENT AND CO-COUNSEL RE: CID RESPONSE (0.3).
FLORENCE MP	09/14/21	0.50	PARTICIPATE IN CALL WITH CLIENT AND CO-COUNSEL RE: CID (0.4); CONFER WITH R. ALEALI RE: FOLLOW UP FROM SAME (0.1).
		0.80	
<b>Total Partner</b>		<b>0.80</b>	
<b>MATTER TOTAL</b>		<b><u>0.80</u></b>	

Purdue Pharma L.P.  
Various Texas Actions

Bill Date: 11/03/21  
Bill Number: 1871267

NAME	DATE	HOURS	DESCRIPTION
BOYLE J	09/20/21	0.60	ANALYZE TEXAS FILINGS AND CORRESPONDENCE FOR RELEVANCE TO PURDUE (0.6).
BOYLE J	09/22/21	0.60	ANALYZE TEXAS FILINGS AND CORRESPONDENCE FOR RELEVANCE TO PURDUE (0.6).
		1.20	
<b>Total Counsel</b>		<b>1.20</b>	
REDMAN R	09/01/21	1.00	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.8).
REDMAN R	09/02/21	0.80	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.6).
REDMAN R	09/07/21	0.80	REVIEW INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.6).
REDMAN R	09/08/21	1.00	ANALYZE INCOMING FILINGS (0.3); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.7).
REDMAN R	09/10/21	1.00	UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (1.0).
REDMAN R	09/13/21	0.90	ANALYZE INCOMING FILINGS (0.3); UPDATE AND ORGANIZE PLEADINGS (0.6).
REDMAN R	09/14/21	1.00	ANALYZE INCOMING FILINGS (0.3); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.7).
REDMAN R	09/15/21	1.20	ANALYZE INCOMING FILINGS (0.3); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.9).
REDMAN R	09/16/21	0.90	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.7).
REDMAN R	09/17/21	1.00	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.8).

**Skadden, Arps, Slate, Meagher & Flom LLP and affiliates**

ATTORNEY WORK PRODUCT

PRIVILEGED AND CONFIDENTIAL

REDMAN R	09/21/21	1.00	ANALYZE INCOMING FILINGS (0.3); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.7).
REDMAN R	09/22/21	1.20	ANALYZE INCOMING FILINGS (0.3); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.9).
REDMAN R	09/23/21	1.20	ANALYZE INCOMING FILINGS (0.3); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.9).
REDMAN R	09/27/21	1.00	ANALYZE INCOMING FILINGS (0.3); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.7).
REDMAN R	09/28/21	0.60	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS (0.4).
REDMAN R	09/29/21	1.10	ANALYZE INCOMING FILINGS (0.3); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.8).
REDMAN R	09/30/21	0.80	ANALYZE INCOMING FILINGS (0.2); UPDATE AND ORGANIZE PLEADINGS AND DISCOVERY (0.6).
		<b>16.50</b>	
<b>Total Legal Assistant</b>		<b>16.50</b>	
<b>MATTER TOTAL</b>		<b><u>17.70</u></b>	

**EXHIBIT E**

**EXPENSE DETAIL**

skadden, arps, slate, meagher & flom llp and affiliates

Purdue Pharma L.P.  
Bankruptcy Related Litigation and Regulatory Issues      Bill Date: 11/03/21  
Bill Number: 1871284

Disbursement	Date	Vendor/Employee/Dept.	Amount
Outside eDiscovery Services	09/30/21	Driven	<u>6,726.31</u>
		<b>TOTAL OUTSIDE EDISCOVERY SERVICES</b>	<b>\$6,726.31</b>
Reproduction - color	09/25/21	Reprographics	<u>16.70</u>
		<b>TOTAL REPRODUCTION - COLOR</b>	<b>\$16.70</b>
Loading Images/Data	09/02/21	Teschky RJ	286.74
Loading Images/Data	09/03/21	Teschky RJ	23.23
Loading Images/Data	09/08/21	Raez R	1,856.60
Loading Images/Data	09/10/21	Lu AQ	<u>300.87</u>
		<b>TOTAL LOADING IMAGES/DATA</b>	<b>\$2,467.44</b>
		<b>TOTAL MATTER</b>	<b>\$9,210.45</b>